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 Pancreatic β-cells perform glucose-stimulated insulin secretion, a process required to 
maintain systemic glucose homeostasis. Obesity promotes glycemic and inflammatory stress, 
causing β-cell death and dysfunction, resulting in diabetes. Efforts to improve β-cell function in 
obesity have been hampered by observations that β-cells are highly heterogeneous, varying in 
morphology, function, and gene expression. There is great need to understand the breadth of β-
cell heterogeneity in health and obesity to improve diabetic therapies. 
High fat-fed SM/J mice spontaneously transition from hyperglycemic-obese to 
normoglycemic-obese with age, providing a unique opportunity to study β-cell adaptation. Here, 
we show that as they resolve hyperglycemia, obese SM/J mice dramatically increase circulating 
and pancreatic insulin levels while improving insulin sensitivity. Immunostaining of pancreatic 
sections reveals that obese SM/J mice selectively increase β-cell mass but not α-cell mass. 
Functional assessment of isolated islets reveals that obese SM/J mice increase glucose stimulated 
insulin secretion, decrease basal insulin secretion, and increase islet insulin content. Next, we 
integrate pancreatic islet single cell and bulk RNA sequencing data to identify β-cell 
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subpopulations based on gene expression and characterize genetic networks associated with β-
cell function in obese SM/J mice.  We assign roles to 4 β-cell subpopulations, whose 
composition is influenced by age, sex, and diet. Network analysis identified fatty acid 
metabolism and β-cell physiology gene expression modules associated with the hyperglycemic-
obese state. We identify subtype-specific expression of Pdyn and Fam151a as candidate 
regulators of β-cell function in obesity. These results establish that improved β-cell function 
underlies the resolution of hyperglycemia, which may be driven by changes in subpopulation 
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Pancreatic β-cells perform glucose-stimulated insulin secretion, a process at the center of type 2 
diabetes etiology. Efforts to understand how β-cells behave in healthy and stressful conditions 
have revealed a wide degree of morphological, functional, and transcriptional heterogeneity. 
Sources of heterogeneity include β-cell topography, developmental origin, maturation state, and 
stress response. Advances in sequencing and imaging technologies have led to the identification 
of β-cell subtypes, which play distinct roles in the islet niche. This chapter reviews β-cell 
heterogeneity from morphological, functional, and transcriptional perspectives, and considers the 
relevance of topology, maturation, development, and stress response. It also discusses how these 
factors have been used to identify β-cell subtypes, and how heterogeneity is impacted by 
diabetes. We examine open questions in the field and discuss recent technological innovations 
that could advance understanding of β-cell heterogeneity in health and disease. 
1.2 Heterogeneity in β-cells, a need for greater understanding 
Pancreatic islet β-cells are optimized to secrete insulin, a process critical for maintaining 
appropriate blood glucose concentration. This requires coordination of glucose sensing and 
metabolism, ATP production via oxidative phosphorylation, insulin biosynthesis, and [Ca2+]-
dependent insulin release1. In type 2 diabetes, peripheral insulin resistance promotes initial β-cell 
expansion, but ultimately results in β-cell death and dysfunction2–4. Therapies include 
Metformin, sulfonylureas, and injection of exogenous insulin, which do not improve long-term 
β-cell function, and have been associated with weight gain, cancer, and hypoglycemic events5–7. 
Current research strategies include ameliorating disrupted β-cell signaling pathways, removing 
dysfunctional β-cells, and improving the β-cell microenvironment8–12. Triggering β-cell 
3 
 
neogenesis, transdifferentiation of other cell types, and inducing β-cell replication are also being 
explored13–16. Many of the therapeutic agents that improve β-cell function are in various stages of 
development17. These strategies require understanding the physiological mechanisms controlling 
β-cell function and are complicated by observations that not all β-cells are alike. 
 Cell sorting, imaging, and sequencing technologies have allowed for analysis of multiple 
β-cell properties, revealing that β-cells vary in morphology, function, and gene expression. 
Drivers of heterogeneity include β-cell topography, developmental origin, maturation state, and 
stress respons18–21. Several groups have proposed that distinct β-cell subtypes exist, and play 
unique roles within the islet22–25. The importance of heterogeneity is reinforced by observations 
that β-cells are subject to variable fates in diabetes including apoptosis, replication, and 
dedifferentiation2,26–28. Characterization of β-cell heterogeneity has led to questions about its role 
in diabetic etiology and therapy29. This review examines current understanding of the breadth 
and sources of β-cell heterogeneity and its relevance to diabetes. Examining heterogeneity lends 
itself to questions about the applications and limitations of β-cell plasticity, which can focus 
research aimed at improving β-cell function. 
1.3 β-cells are morphologically and functionally heterogeneous 
 Histological assessment of the pancreatic islets show β-cells vary in basic morphology, 
including larger cells with large nuclei that localize near the islet center30,31. Increased nuclear 
size is attributed to polyploidy; β-cells are the only endocrine cell type observed in tetra- and 
octoploid states32. The cause of polyploidy in β-cells is linked to metabolic stress, as mean 
nuclear size and incidence of polyploidy increase in diabetes32–35. β-cells exhibit morphological 
variation in other organelles, with central β-cells exhibiting enlarged endoplasmic reticulum (ER) 
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and Golgi apparatuses following short glucose exposure36. Other features that distinguish central 
from peripheral β-cells include mitochondrial morphology, number of insulin granules, and 
number of cell-cell contacts34,37–40. Most β-cells exhibit polarity, consisting of an apical face 
where primary cilia project into extracellular space, a lateral face where glucose uptake and 
insulin secretion occur, and a basal face connected to vasculature, forming a rosette-like structure 
around capillaries41–44. Further, β-cells with atypical cellular organization have also been 
identified, including nonpolar cells and cells with apical mRNA localization23,45. β-cells display 
observable cell cycle variability, with <0.5% of adult human β-cells and 2% of adult mouse β-
cells displaying markers of mitosis46,47. This replication rate is increased in obesity, pregnancy, 
and with glucocorticoids48–51. Clearly, β-cells vary in basic cellular features, and experiments 
reveal that β-cell function is equally diverse. 
 Glucose-stimulated insulin secretion has been characterized in depth52–55. Glucose is 
converted to pyruvate through glycolysis initiated by glucokinase (Gck), then promotes ATP 
production through the Citric Acid Cycle and oxidative phosphorylation, which triggers 
membrane depolarization and [Ca2+]-dependent insulin release. Fluorescence-activated cell 
sorting (FACS) based on metabolic activity of individual β-cells using NADPH autofluorescence 
revealed 25% of rat β-cells do not increase activity in high (20mM) glucose conditions56. A 
follow-up study examined metabolic responders and non-responders at 7.5mM glucose57. 
Responders enter first phase insulin secretion at lower glucose concentration and secrete more 
insulin, despite having similar insulin stores. This is attributed to preferential secretion of newly 
synthesized insulin over stored insulin and is supported by work showing insulin biosynthesis is 
stimulated by glucose and that responsive cells are enriched for proinsulin-rich granules58,59. 
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Thus, glucose sensitive cells produce and release mature insulin granules rapidly, resulting in 
elevated proinsulin/insulin ratio. Dispersed human β-cells display variation in insulin secretion, 
with 20% of cells secreting 70-90% of insulin60,61. Sorting β-cells based on metabolic activity at 
16.7 mM glucose revealed metabolically responsive β-cells are larger in size62. Controlling for 
cell size shows metabolically active and inactive cells secrete similar amounts of insulin. Thus, 
insulin secretion is influenced by cell size, linking β-cell morphology and insulin secretion. This 
evidence was corroborated by observations that larger, central β-cells degranulate faster than 
peripheral cells in vivo in response to hyperglycemic conditions36. Observations that insulin 
secretion varies between β-cells has been confirmed by a variety of techniques including patch-
clamp measurements and 3D imaging63–65. 
Glucose sensitivity is associated with higher expression of glycolytic and protein 
biosynthesis genes and correlates with the glucose phosphorylation activity of Gck66,67. 
Treatment with glyceraldehyde bypasses glucose phosphorylation to induce metabolic activity in 
glucose-unresponsive cells at low glucose concentrations but cannot exceed maximum glucose-
induced insulin biosynthesis, suggesting Gck activity is the rate limiting step in insulin synthesis 
and secretion68. Giordano et al. assessed the stability of glucose sensitivity during repeat glucose 
exposure using a hemolytic plaque technique to measure insulin secretion69. They found 75% of 
β-cells were consistently responsive or unresponsive following 3 glucose exposures, while 25% 
of β-cells switched between states, suggesting glucose sensitivity fluctuates in a subset of cells. 
Glucose sensitivity is predictive of susceptibility to mitotic stimuli and protection against 
oxidative damage and apoptosis, hinting at how cells would fare in diabetes51,56,70. Collectively, 
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these observations highlight the breadth of phenotypic variation in β-cells, motivating studies 
aimed at understanding the mechanisms underlying these differences. 
1.4 Heterogeneity in gene and protein expression 
 Many genes in the insulin secretion pathway display heterogeneous expression and have 
a direct impact on β-cell function. Glucose import through Glut2 is the first step in the insulin 
secretion pathway and is inhibited in STZ-induced diabetes in mice71. Heterogeneous Glut2 
expression has been reported in several studies and may be indicative of maturation state and 
replicative potential25,45,72–76. The rate-limiting enzyme Gck is variably expressed among β-cells, 
correlating with glucose sensitivity, Glut2 levels, and number of insulin granules67,77. Metabolic 
perturbations influence Gck expression, which precede changes in Ins2 expression, suggesting a 
regulatory role in insulin production78. Variation in insulin gene expression and protein levels 
has been observed in many studies23,38,74,78,79. Central β-cells contain less insulin protein than 
peripheral β-cells, a distinction that disappears with fasting78. Using an insulin promoter 
construct linked with GFP, Katsuta et al. used FACS to separate β-cells containing low, medium, 
and high levels of insulin protein38. Medium level β-cells comprised 70% of cells, and the low 
insulin population had diminished insulin gene expression and secretion. Variable expression of 
these components may directly contribute to the heterogeneity seen at the phenotypic level. 
 Other gene markers of β-cell heterogeneity with a less direct connection to insulin 
secretion have been identified. These include cell-cell adhesion genes like the sialylated form of 
neural cell adhesion molecule (PSA-NCAM)80. FACs sorting β-cells into PSA-NCAM-high and 
-low populations revealed that expression correlates with glucose-stimulated insulin 
secretion73,81,82. PSA-NCAM-low cells have less Ca2+ influx following glucose exposure, 
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reduced ATP levels, and decreased expression of Glut2 and Gck. Morphologically, PSA-NCAM 
knockout cells differ in f-actin distribution, altering cell polarity80. The proportion of PSA-
NCAM-high cells increases in diabetes73. Whether NCAM is heterogeneously expressed in 
humans is unknown. β-cells can be sorted based on expression of E-cadherin, which promotes 
islet formation and compaction83–85. Like NCAM, sorting β-cells into E-cadherin-high and-low 
populations revealed that higher expression is associated with increased glucose-stimulated 
insulin secretion and insulin expression83. Further, glucose induces E-cadherin expression and 
causes dispersed β-cells to aggregate in vitro84. Other variably expressed genes include Npy, Th, 
Vmat2, and Dickkopf-386–89.  
 Several studies have identified β-cell subpopulations based on variation in global gene 
expression. Baron et al. found two subpopulations in nondiabetic donors driven by variable 
expression of ER-stress response genes including HERPUD1, HSPA5 and DDIT3, which 
correspond with low expression of genes associated with β-cell function including UCN3, 
MAFA, and NEUROD190. This heterogeneity was lost in hyperglycemic samples. Similarly, 
Muraro et al. identified 3 β-cell populations, one of which had elevated expression of stress 
response genes HERPUD1 and HSPA1B91. Importantly, Muraro et al. validated these findings 
using RNA-FISH on intact islets to rule out isolation-induced stress. Xin et al. identified four 
subpopulations in human β-cells, one of which differentially expressed 431 genes21. This 
subpopulation had low insulin expression and elevated expression of ER-stress and UPR-
associated genes. Fang et al. profiled 9,964 β-cells from healthy and diabetic donors and 
identified a subpopulation enriched for expression of heat shock proteins92. Lastly, Segerstolpe et 
al. identified 5 subgroups based on expression of RBP4, FFAR/GPR120, and ID family 
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transcription factors93. RBP4 expression is associated with insulin resistance, while ID 
transcription factors are associated with cell cycle activity94,95. Several groups have failed to 
detect β-cell subpopulations; however, many were limited by the number of β-cells analyzed96–
101. Despite little consensus in the genes that may drive heterogeneity, an emerging pattern 
suggests β-cells differ in expression of genes related to stress response.  
 The limitations of single cell technology explain some of the discordance among studies. 
These shortcomings are highlighted in a meta-analysis from Mawla and Huising, who examined 
discrepancies across five single cell RNA sequencing studies90,91,93,97,99,102. Pooling β-cells across 
all studies revealed 2 populations of β-cells driven by differential expression of 52 genes. These 
include genes associated with other endocrine and exocrine cell types, but not stress response. 
Only 3 genes had previously been associated with β-cell heterogeneity: RBP4, DLK1, and 
HERPUD1. When subset into cells from healthy donors, only 24 genes were differentially 
expressed across β-cells. Among these, only NPY has been previously associated with β-cell 
heterogeneity. This lack of correspondence among studies is a concern. Only 86 genes were 
detected in all β-cells within the aggregated data. This contrasts with the hundreds of 
housekeeping genes required for cellular function103. β-cells express at least 18,000 genes, thus 
99.5% of genes are inconsistently captured21,93. With current methodology, the capture of most 
genes is likely due to technical artifacts or random chance, and not intrinsic biological 
variation104. Methods for preprocessing and noise removal are being developed to aid in quality 
control, including tools that remove cell doublets, remove ambient RNA, assess transcript 
coverage, and provide imputation for gene dropout105–108. In human studies, donor age and 
isolation procedure likely contribute to discordance among studies but are seldom controlled for. 
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Further, many groups report differential expression of genes between subsets of β-cells, but 
effect size is rarely reported or discussed. As technological advances increase single cell 
sequencing read depth, profiling of thousands of cells all but guarantees statistically significant 
differential expression based on p-values alone. Discussions about whether these differences are 
meaningful will be increasingly important, and will be aided by measuring effect size109. 
 Dorrell et al. used FACS to identify 4 subpopulations based on expression of human β-
cell surface markers CD9 and ST8SIA1110. They designated these populations as β1–4, where 
β1/ β2 cells are positive for ST8SIA1 and β3/β4 are ST8SIA1 negative. There are 125 genes 
differentially expressed across groups, while gene ontology enrichment analysis revealed β1/β2 
cells are enriched for protein secretion, while β3/β4 cells are enriched for neurogenesis. This 
corresponds with β1/β2 populations having greater glucose-stimulated insulin secretion, while 
β3/β4 have elevated basal insulin secretion. The proportions of these populations are altered in 
diabetic individuals, suggesting they differ in susceptibility to metabolic stress, with the caveat 
that inter-patient variation is much higher than variation between healthy and diabetic donors. 
How these markers of heterogeneity are tied to β-cell function remain areas of interest. It is 
possible that these populations have separate roles within the islet niche, with β1/β2 cells 
specializing in glucose-stimulated insulin secretion, and β3/β4 cells specializing in basal insulin 
secretion. 
 The potential existence of specialized basal insulin secreting β-cells is supported by 
Farack et al., who used smFISH to identify a subpopulation of mouse β-cells with elevated 
insulin expression23. These cells, termed “extreme” β-cells, represent ~7% of β-cells, and 
localize near the islet center. Extreme β-cells have a distinct polarization pattern, high pro-insulin 
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and ribosomal RNA content, and less mature insulin protein. They have elevated expression of 
Ins1, Iapp, Chga, and Pcsk2 which are associated with insulin secretion. Thus, the authors 
suggest that these cells are producing and quickly secreting high levels of insulin, so they 
maintain a high proinsulin/insulin ratio despite having other markers of β-cell maturity. The 
proportion of extreme β-cells increase in db/db mice, suggesting they may play a role in 
glycemic stress response. These findings are summarized in Figure 1.1. Could these extreme β-
cells overlap with the β3 and β4 populations identified by Dorrell et al.110? Or with PSA-NCAM-
low and E-cadherin-low cell populations? Answers to these questions may provide insight into 
how to remedy the dysregulated glucose-stimulated insulin secretion seen in diabetic islets. 
Discussed below are 4 factors that influence β-cell behavior: topology, development, maturation, 
and stress response. These factors provide insight into how β-cell heterogeneity is maintained, 
and how it may be harnessed for therapeutic purposes. 
1.5 Topography influences β-cell heterogeneity 
In addition to β-cells, islets contain α-cells, 𝛿-cells, ε-cells, γ-cells, as well as non-
endocrine cells including endothelial cells, macrophages, glia, fibroblasts, and pericytes61,111. 
Mice and humans have different islet compositions, which may explain why few discoveries 
from rodents validate in humans42,61,112,113. Mouse islets are comprised of 60-80% β-cells and 15-
20% α-cells. β-cells localize to the center, or core, of the islet, while α- and 𝛿-cells localize to the 
periphery, or mantle. Human islets are comprised of 50% β-cells and 40% α-cells. Recent 
imaging efforts suggest human islets comprise small repeating clusters of the β-cell core, α-cell 
mantle pattern42,113,114. Further, location within the pancreas influences islet cell composition. 
Islets in the pancreatic head are enriched for γ-cells, while islets enriched in α-cells are found in 
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the neck. The proportion of β-cells per islet increases from head to tail of pancreas115–117. Islets in 
the tail of the pancreas degranulate faster than head islets in vivo following prolonged glucose 
exposure, and have higher rates of replication, insulin synthesis, and secretion36,118–120. Human 
islets near the pancreatic head tend to be less spherical than those found in the tail, which may 
influence cell-cell communication121. NCAM plays a role in islet organization, as NCAM 
knockout mice have altered islet cell composition, including α-cell infiltration into the islet 
core80. Both humans and mice display altered islet composition in diabetes, including deviation 
from the mantle-core arrangement122,123. β-cell loss is more pronounced in γ-cell-rich islets 
within the head of the pancreas in diabetes120. β-cells in the splenic region of the pancreas 
undergo proliferation during diabetes, while those near the head do not56. 
 As previously discussed, β-cells near the islet core exhibit morphological and functional 
differences from those in the periphery31,36,78,124–126. These differences are attributed to the homo- 
and heterotypic connections maintained by each cell, a result of the mantle-core architecture of 
the islet, in which core β-cells are enriched for homotypic contacts127. Dispersed β-cells secrete 
less insulin in response to glucose than β-cells in an intact islet128,129. β-cells coupled with other 
β-cells secrete more insulin than individual β-cells, while β-α-cell couplings produce more 
insulin than individual β-cells, but less than β-β-cell coupling60,129,130. Peripheral β-cells have 
more heterotypic contacts with somatostatin-secreting 𝛿-cells, which inhibits insulin 
secretion124,131–134. Importantly, comparisons between core and peripheral β-cells in islets 
cultured ex vivo are confounded by the rapid onset of hypoxia in the islet core following 
isolation, particularly in large islets135–137. It is critical that observations comparing each 
population are verified using complementary methods. Primary cilia influence β-cell function by 
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facilitating communication with neighboring cells, and further exploration is needed to see if 
they play a role in maintaining heterogeneity138,139. The morphological and functional differences 
between core and peripheral β-cells may be derived from connections to other β-cells, α-cells, or 
𝛿-cells, which in turn is influenced by the location of the islet within the pancreas (summarized 
in Figure 1.1C). 
Within each islet, small clusters of β-cells synchronize Ca2+ fluctuations140. This is 
attributed to gap junctions between β-cells coordinating insulin release and may explain why 
coupled cells secrete more insulin than isolated cells39,124,141,142. Gap junctions are 
heterogeneously expressed across the  population39,40,141,143. A subpopulation of hyperconnected 
β-cells has been proposed24. These “hub” cells were identified by quantifying the number of 
significant pairwise correlations of glucose-stimulated Ca2+ oscillations that each cell 
maintained. These cells represent 1-10% of all β-cells and control the activity of “follower” cells 
by coordinating Ca2+ signaling through gap junctions. These cells express high levels of Gck and 
genes involved in glucose oxidation, but low levels of insulin, and have accelerated and extended 
Ca2+ signaling during glucose stimulation. Ablation of hub cells disrupts Ca2+ synchronization 
across the islet, while ablating follower cells had no effect. These cells are sensitive to diabetic 
insults, which could explain why Ca2+ coordinated insulin release is disrupted in diabetes. These 
findings are summarized in Figure 1.1E. Salem et al. built upon this model, showing 
transplanted islets contain hyperconnected β-cells, termed “leader” cells, that trigger a wave of 
calcium release across the islet 144. The role of hub/leader cells have been challenged, because 
the mechanisms through which hyperpolarizing hub cells inhibit Ca2+ coordination among other 
cells is unclear145. The relevance of such a subpopulation has been questioned, as disrupting Ca2+ 
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signaling in ~70% of β-cells does not alter insulin secretion, suggesting other mechanisms are of 
greater importance146–148.  Further, knockout of the gap junction protein Cx36 in mice results in 
altered calcium synchronization, but has minimal effect on overall insulin release, suggesting 
Ca2+ signaling is influential but not critical for β-cell function149,150. 
 Vascularization and innervation also vary amongst islets and provide a template for 
heterogeneity. Capillaries provide nutrients, oxygen, and ECM support to islets, which improve 
insulin secretion and promote cell survival151–153. Small islets have 2-3 vascular penetrations, 
large islets have >3, resulting in β-cells receiving unequal access153. Islets in the pancreatic 
periphery receive capillary branches, while islets at the center directly contact large blood 
vessels153. Several groups have proposed the existence of two classes of islets based on 
vascularization, high-perfused and low-perfused154–156. High-perfused populations represent 75% 
of islets, have higher glucose-stimulated insulin secretion and greater rates of β-cell replication, 
but are susceptible to cytokine induced cell death and hypoxia154–156. These differences are 
attributed to capillaries increasing oxygen tension within β-cells155. The low-perfused islets 
appear to serve as reserves and are recruited to activity when metabolic demand increases154,155. 
β-cells organize themselves around capillaries in rosette structures, with insulin granules 
localizing towards the capillary and driving polarity41,42. Evidence suggests blood typically flows 
from islet core to mantle, from β-cells, to α-cells, then 𝛿-cells153,157–159. This may bias 
directionality of cell-cell communication among endocrine cells159,160. Innervation also impacts 
islet development, maturation, mass, and function161–163. While only a small number of β-cells 
receive axon terminals, which tend to reside in the islet periphery, neurotransmitters including 
serotonin and GABA promote β-cell replication164–167. Human islets have less innervation than 
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mouse islets, which may explain why they have lower regenerative capacity168. However, it is 
unclear if differences in biological age between mice and human donors confound these findings. 
Clearly the location of the β-cell within the islet, and the islet within the pancreas, influences β-
cell exposure to nutrients and potentially harmful milieu. As β-cell heterogeneity is explored in 
greater depth, topology may aid in understanding why cells behave differently. 
1.6 Developmental origin influences β-cell heterogeneity 
 The pancreas arises from two epithelial evaginations in the foregut, termed the dorsal and 
ventral buds, which give rise to the head and tail regions, respectively169. Despite differences in 
blood supply and innervation, both buds contain endocrine progenitor-precursor cells, which 
give rise to nascent β-cells169–172. Using chimeric mice, Deltour et al. showed that individual 
islets contain β-cells with different developmental origins, suggesting β-cells are not monoclonal 
within the islet173. Nascent β-cells undergo an initial period of replication, peaking at 20 weeks 
gestation174. β-cell replication remains high at birth, then declines rapidly with age, resulting in a 
several-fold expansion of β-cell mass between birth and adulthood175. β-cell telomere length 
diminishes over time, particularly during the first two months of life, when β-cell proliferation is 
at its highest176. Further, 4-month-old mice display greater variability in telomere length among 
β-cells compared to 12-day old mice, suggesting replication is not uniform across the population. 
In adult mice, β-cell replication is the principle mechanism for maintenance of β-cell mass, 
driven by a small number of mitotically competent cells, which declines with age47,177–179. The 
number of replicating β-cells increases under metabolic stress and inflammation, but this effect is 
also restricted by age48,51,175,180–182. Several other markers have been associated with β-cell aging 
and functional decline, including expression of IGF1R and P53BP1, and increased lipid 
15 
 
storage183,184. The degree of heterogeneity displayed by these markers is unknown. While β-cell 
replication plays a central role in generating and maintaining β-cell mass, the notion that it is the 
sole mechanism for β-cell replacement has been challenged. 
 Insulin positive cells are observed in ductal tissue following partial pancreatectomy and 
overexpression of gastrin and TGFα in ductal cells185–188. Prolonged glucose infusion induces 
ductal clusters to become PDX1 positive, with some expressing insulin189. These extra-insular β-
cells are also proliferative, as they are observed in aggregates <50 µm190–192. Like low-perfused 
islets, ductal cells may provide a reserve pool of insulin production during glycemic stress. 
Several groups have identified a pancreatic multipotent progenitor (PMP) population25,76,193,194. 
These cells express insulin but lack Glut2 expression, likely preventing them from performing 
glucose-stimulated insulin secretion. Interestingly, these cells have the capacity to proliferate and 
generate multiple endocrine cell types, including functional β-cells. Further, replication of these 
cells is induced by hyperglycemic conditions, suggesting they too may play a role in glycemic 
stress response. The existence of PMPs has been heavily challenged, as other studies fail to 
identify such populations, even following substantial β-cell loss177,195,196. Much of the argument 
centers on the weaknesses of lineage tracing, reviewed in197, and the low likelihood that these 
cells contribute meaningfully to functional β-cell mass. What relationship, if any, exists between 
ductal-derived β-cells and PMP’s remains to be characterized. 
  α-cells have been shown to acquire β-cell-like properties in response to extreme β-cell 
loss and genetic perturbations198–202. However, the utility of these observations is questioned 
because of lack of evidence that this phenomenon occurs in normal islet homeostasis. A study by 
van der Meulen et al. addressed some of these criticisms by identifying a Glut2-low population 
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of β-cells residing within the islet periphery72. Using lineage tracing, they showed that these 
“virgin” β-cells do not express Glut2 because they are an intermediate in α-to-β-cell 
transdifferentiation. These cells do not import meaningful amounts of glucose following 50 
minutes of exposure and are resistant to STZ-induced β-cell death, likely due to lack of Glut2 
expression. These cells transition into Glut2-high β-cells overtime, making them 
indistinguishable from conventional β-cells. A recent study challenged that Glut2-low cells 
represent an α-β transitional cell, and that massive β-cell loss induces transdifferentiation203. 
Feng et al. used an STZ model of diabetes to assess the fates of Glut2-high and Glut2-low β-cells 
using single cell RNAseq. While Glut2-low β-cells survive STZ treatment, they do not mature 
into Glut2-high cells in 9 months post-treatment, contradicting van der Meulen et al.’s findings72. 
Further, they did not find evidence for α-β-cell transdifferentiation at the transcriptional level. 
However, these mice were given insulin pellets to ensure long-term survival, which may 
confound interpretation. Regardless of their relevance to normal insulin homeostasis, the 
transdifferentiation of ductal or α-cells into β-cells remains an appealing therapeutic approach for 
diabetes. Neither ductal or α-cell populations are reduced by diabetes, providing a steady source 
of potential β-cells. Further, α-cells display a high degree of resistance to viral and metabolic 
induced stress, suggesting that β-cells derived from α-cells could retain these properties204,205. 
The potential sources for β-cells are summarized in Figure 1.1A. At this junction, it is not clear 
how β-cells from different developmental sources display meaningful heterogeneity. Given the 
influence of the β-cell microenvironment on function, there is no reason to believe β-cells from 
dorsal or ventral islets, β-cell replication, differentiation of PMPs, or transdifferentiation of β-
cells would behave identically. Understanding how β-cells functionally mature will provide 
insight into how β-cell location, age, and function interconnect. 
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1.7 Maturation influences β-cell heterogeneity 
 How β-cells acquire specialized functionality has been characterized in depth. In mice, 
initial β-cell maturation proceeds in two developmental phases206–209. The first phase lasts two 
weeks following birth, a period of rapid β-cell proliferation and simultaneous waves β-cell 
apoptosis, which coordinate to set the foundation for β-cell mass210,211. Surviving cells begin to 
express transcription factors required for β-cell function and are considered immature172,206,212. 
The second developmental phase starts at weaning, characterized by changes in metabolic 
pathways and functional maturation209,213. Comparing β-cells from 4-week old mice and 16-week 
old mice reveals differential expression of thousands of genes, while only 193 genes were 
differentially expressed between 3- and 26-month old mice, suggesting β-cells change 
substantially early in life and little in adulthood96,214. Pseudotime analysis of individual β-cells 
reveals differential expression of genes associated with amino acid uptake, ROS production, and 
cellular respiration during functional maturation101,178. Markers of mature β-cells include Glut2, 
Ins2, Mafa, Nkx6.1, NeuroD, and Ucn3 while immature β-cells express Hk1, PaxA, Pax6, and 
Mafb3,215–218. In humans, MAFB is expressed in mature β-cells and knockout of MAFB results in 
β-cell dysfunction, suggesting it plays a nonredundant role from MAFA219–221. A set of 
“disallowed” genes including Hk1, Ldha, Mct1, Rest, and Pdgfrα, have been identified as being 
prohibited from expression in mature β-cells213,222,223. Many of these genes are involved in 
glucose metabolism and exocytosis and would interfere with glucose-stimulated insulin 
release224. The molecular machinery driving insulin release is similar in both mature and 
immature β-cells, with a few key differences218. Neonatal islets have elevated basal insulin 
secretion due high glucose sensitivity218,225. Interestingly, when immature and mature β-cells are 
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depolarized independent of glucose sensing, both release similar levels of insulin, suggesting 
their differences lie in glucose sensing and metabolism218. Immature β-cells express Hk1, which 
has a higher affinity for glucose than Gck, which is expressed in mature β-cells226–228. Thus, it 
takes higher concentrations of glucose to trigger glycolysis and downstream oxidative 
phosphorylation in mature β-cells, which may explain differences in insulin secretion between 
these two classes of cells. Other components of the insulin secretion pathway, including genes 
involved in glycolysis, the TCA cycle, oxidative phosphorylation, and exocytosis are also 
differentially expressed between mature and immature β-cells209,213,229. An overview of immature 
β-cell characteristics is shown in Figure 1.2A. 
 Maturation state appears to be a heterogeneous trait in adult β-cells and is associated with 
replicative capacity214,230,231. Szabat et al. used a Pdx1/Insulin dual reporter to discover that 25% 
of β-cells in humans and mice are Pdx1 positive but have low insulin expression74. These cells 
have an immature gene expression profile, including elevated Mafb expression, and low Gck and 
Glut2 expression. Immature cells have high proliferative capacity and poor insulin secretion, and 
functionally mature without proliferation in vitro. Bader et al. reinforced these findings by 
identifying a subpopulation of immature β-cells based on lack of Fltp expression (discussed 
below)45 These cells have high replicative capacity at the expense of mature β-cell function. The 
replication/maturation dichotomy was illustrated by Klochendler et al., who used a fluorescent 
reporter mouse for cyclin B1, which is active only during mitosis230. This allowed sorting of cells 
based on a mitotic state. Performing RNAseq on these populations revealed a global increase in 
cell cycle genes, but a distinct downregulation of genes associated with β-cell function including 
Glut2 and Ucn3 as well as enrichment for genes regulated by mature β-cell transcription factors. 
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In human β-cells, a clustering approach to simultaneously assess intracellular Ca2+ dynamics in 
~300 islet cells revealed two distinct populations based on Ca2+ flux frequency and amplitude, 
suggesting mature and immature states232. The dichotomy between replication and maturation is 
associated with ER stress response178,233. These observations have implications for understanding 
post-natal β-cell expansion; individual β-cells cannot simultaneously replicate and be functional. 
 Observations that β-cell replication and maturation are at odds were coalesced into a 
unified theory by Bader et al., who separated β-cells into mature and immature populations based 
on expression of Flattop (FLTP)45. FLTP is expressed in tissues where the Wnt/Planar cell 
polarity pathway is active and is necessary for epithelial organization and architecture234. Bader 
et al. used an islet specific FLTP reporter and found expression increases throughout β-cell 
maturation, resulting in 80% of cells positive for FLTP in adult mice. Transcriptional analysis 
revealed 997 genes differentially expressed between populations, with positive cells expressing 
markers of maturation including Ucn3, Mafa, mitochondrial oxidative phosphorylation genes, 
and insulin secretion genes, while negative cells expressed genes associated with MAP kinases, 
Gcprs, and had low Glut2 expression. FLTP(-) cells are more proliferative, with 8% of negative 
cells staining Ki67(+) at postnatal day 11, compared to 2% of FLTP(+) cells. In high fat diet-
induced islet hypertrophy, the FLTP(+) population expanded in line with heightened metabolic 
demand, suggesting that the progeny of FLTP(-) cells can become FLTP(+). Morphologically, 
FLTP(+) cells are polarized and found in rosette structures. Re-aggregated FLTP(-) cells in vitro 
have lower glucose stimulated insulin secretion than positive cells, suggesting they are 
functionally immature. Knockout of FLTP resulted in very mild functional changes, suggesting 
FLTP is a passive marker for maturation. In humans, islet FLTP expression correlates with 
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glucose tolerance, with healthy donors expressing higher levels of FLTP than prediabetic and 
diabetic donors. Thus, FLTP distinguishes proliferative and metabolically active β-cells and 
suggests β-cell maturation could be driven by the polarization process. The specific mechanism 
through which the wnt/PCP pathway effects β-cell function is unknown, but it may involve 
cytoskeleton components and gene expression changes. These findings raise questions about β-
cell heterogeneity. Are FLTP(-) cells part of the 25% of β-cells that do not increase metabolic 
activity in high glucose56? Could these be the Glut2-low cells reported in PSA-NCAM low cells 
or E-cadherin low cells73,81–83? Or the poor functioning β3 and β4 cells identified by Dorrell et 
al.110? It is possible that many of these studies are converging on overlapping populations of 
cells. The differences between immature and mature β-cells are highlighted in Figure 1.1B and 
Figure 1.2B.  
 Dedifferentiation of mature β-cell identity is a central component of β-cell dysfunction in 
type 2 diabetes215,235–239. This is attributed to many factors, including oxidative stress, glucose 
and lipid toxicity, and inflammation235,240–242. Dedifferentiated β-cells have decreased insulin 
expression and decreased insulin secretion, thus contributing to loss of glycemic control3,93,240. 
Dedifferentiation is characterized by decreased expression of β-cell-specific transcription factors 
Pdx1, Nkx6.1, and MafA, increased expression of developmental genes, Ngn3, Oct4, Nanog, and 
L-myc, and expression of disallowed genes, Ldha, Mct1, G6pc, and Hk126,222,242–244. These 
changes are linked to decreased expression of Foxo1, which mediates Pdx1 activity3,26,245–247. An 
overview of the characteristics of dedifferentiated β-cells is shown in Figure 1.2C. Moving 
hyperglycemia-induced dedifferentiated β-cells into a healthy environment can reverse the 
dedifferentiation phenotype215,236,248. Insulin administration can also return immature cells to a 
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functional state, suggesting therapeutic intervention is possible238. We recently published 
findings on obese SM/J mice, which spontaneously transition from hyperglycemic-obese to 
normoglycemic-obese with age249. Underlying this transition is improved β-cell function, 
including increased insulin content and glucose-stimulated insulin secretion. This suggests SM/J 
β-cells are likely undergoing maturation and show that β-cell functionality can be improved in 
vivo in the context of obesity. Evidence for dedifferentiated β-cells in diabetic humans based on 
single cell RNA sequencing data has been established98. The parallels between nascent β-cell 
maturation and diabetes-induced dedifferentiation have not been fully explored. Greater 
understanding of the β-cell maturation process may provide insight into how dedifferentiated β-
cells may be rescued, opening exciting new avenues for therapeutic interventions. 
1.8 Stress response influences β-cell heterogeneity 
 An emerging paradigm suggests that β-cells undergo cycles of insulin production and 
stress response, due to the unique physiological demands they face. Insulin synthesis accounts 
for 10% of total protein during basal conditions, compared to 50% in stimulated conditions59,250. 
Insulin is highly prone to misfolding251–253. Once misfolded, insulin can be refolded or degraded. 
Under demanding conditions, misfolded proteins accumulate, and the UPR machinery is 
activated to clear the misfolded proteins254. The high rate of oxidative phosphorylation in β-cells 
also generates ROS, which can damage nascent proteins255. β-cells have been characterized as 
having low antioxidant defense, and thus are more susceptible to stress256,257. This combination 
of factors make the insulin secretion responsibilities of β-cells a unique cellular challenge. 
 Many single cell studies identified subpopulations of β-cells based on an ER stress 
response signature, at the expense of genes related to mature β-cell function21,90,92,258. Xin et al. 
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performed pseudotime analysis on human β-cells and identified the transcriptional trajectory 
between the three β-cell states: High Insulin/Low UPR, Low Insulin/High UPR, and Low 
Insulin/Low UPR21. This suggests mature β-cells undergo a cycle: Elevated insulin production, 
followed by a period of low insulin production and UPR activation to clear misfolded insulin 
protein, then a rest period of low insulin and low UPR activity. Under this hypothesis, only a 
fraction of β-cells produce insulin at a given time while others are resting/recuperating259. This is 
supported by evidence from isolated human and mouse β-cells, where a small fraction of cells 
are responsible for the majority of insulin secretion57,60,61. Xin et al. also found Low Insulin/High 
UPR cells were more proliferative, suggesting they are given the chance to replicate during 
recovery21. Cells under glycemic stress would produce more insulin, thus would have a great 
degree of UPR activation. Whether replication is induced by the intensity or length of UPR 
response is unknown. This theory is supported by Szabat et al., who used a Pdx1/INS dual 
reporter to show that β-cells transition between periods of high and low insulin in ~27 hour 
cycles259. Activation of UPR in human β-cells also stimulates proliferation233. A summary of β-
cell stress response cycling is summarized in Figure 1.1D. Could the interplay between these 
metabolic states explain the morphological, functional, and transcriptional heterogeneity seen in 
β-cells, particularly the identification of β-cell subpopulations in single cell RNAseq data? Loss 
of β-cell mass by apoptosis occurs in diabetes, driven in part by failure of the ER stress response. 
In response to prolonged stress, what drives β-cells to undergo apoptosis, dedifferentiation, or 






 Our understanding of β-cell heterogeneity has increased over decades, revealing several 
trends. First, there is a morphological and functional dichotomy between peripheral and core β-
cells31,36,125. This is attributed to topology including homotypic contacts, heterotypic contacts, 
vascularization, and proximity to axon terminals60,124,127,129,153,164. Further, islet topology changes 
in diabetes, highlighting the importance of understanding the role of the β-cell 
microenvironment120,122,123. The developmental origins of the β-cell, including neogenesis, β-cell 
replication, and differentiation from another cell may play a role in heterogeneity. These 
different sources produce adult β-cells that vary in cellular age, which is associated with 
functional decline176,183,184. How the distribution of young and old β-cells influences islet 
function and stress response is unknown, but it clearly influences replicative capacity177–179. The 
existence and relevance of ductal cell-, α-cell-, and PMP derived-β-cells remains controversial, 
but they are appealing avenues for diabetic therapy because of their stress resistance 
characteristics72,76,185,203–205. β-cell function and replication are at odds during the initial 
maturation process, resulting in decreased mitotic index and improved glucose-stimulated insulin 
secretion172,209,213,215,216. In adults, a subpopulation of cells retain immature gene expression and 
functional characteristics, including higher replication rates45,74,230,232,260. Loss of mature β-cell 
identity is a hallmark of diabetes and disrupts the insulin-glucose axis215,235–237. Can studying the 
differences between immature and mature β-cell populations in healthy adults inform diabetic 
therapy? Variation in β-cell metabolic activity is associated with differences in stress 
susceptibility, suggesting mature and immature populations likely succumb to different fates in 
diabetes51,56,154–156. The relationship between β-cell maturation, replication, and stress response is 
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complicated by observations that mature β-cells undergo a stress response cycle, and that UPR 
activation can stimulate replication21,178,233,259. The relationships among classes of variation, 
sources of variation, and proposed subtypes is summarized in Figure 1.1. These likely contribute 
to the variance seen in single cell RNA sequencing studies, many of which cluster cells based on 
expression of stress response genes21,90,92,258. 
 Assessment of variation in gene expression, protein levels, morphology, and function has 
led several groups to identify β-cell subpopulations. Given the frequency of these populations, 
there is likely substantial overlap. This includes FLTP (-), ST8SIA1 (+), PSA-NCAM-low, E-
Cadherin-low, and Glut2-low “virgin” β-cells all possibly identifying adult immature β-cells 
based on gene expression and functional characteristics45,72,81,83,260. How much of the 
transcriptional heterogeneity identified in single cell RNA sequencing is driven by the ER stress 
response cycling21,90,258,259? Further, does ER stress response cycling influence the immature β-
cell population? This could explain the elevated, but not dramatic increase in β-cell replication 
seen in immature cells. These observations raise questions over requirements for subtype 
classification. Are subtype traits under unique selective pressure, different from the general 
population? What are the temporal requirements for a subtype? What about cell plasticity, the 
ability of subtypes to interconvert? Should a subtype require a unique functional and 
transcriptional profile? Answering these questions will clarify which heterogeneous traits are 
critical for building subtype identities. 
 Techniques including FACS and single cell RNA sequencing are mainstays in shaping 
understanding of β-cell heterogeneity. However, these techniques have limitations, as they fail to 
capture functional, transcriptional, and topological information simultaneously. Further, 
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questions about the temporal regulation of β-cell heterogeneity are becoming unavoidable. 
Lineage tracing is the gold standard for understanding developmental trajectories but has 
received considerable criticism for its shortcomings including promoter leakage, low labeling 
efficiency, and inability to recapitulate native expression patterns197. Dual trace techniques may 
overcome some of these issues261. Several new techniques promise to improve our understanding 
of β-cell heterogeneity, including preserving live sections using perfluorocarbon262,263. This will 
allow temporal and topological assessment of β-cells and provide the opportunity to test the 
effects of various compounds on β-cell growth and function in vivo. This will also provide a new 
platform for lineage tracing. SeqFISH allows one to probe the expression of hundreds of genes 
simultaneously in intact tissue, which can couple extensive transcriptional information with 
topology264. Patch-Seq couples β-cell ion-channel activity with single cell RNA sequencing, 
linking functionality with gene expression63. This is an exciting time to be in the field of β-cell 
heterogeneity, as many of the discoveries made over decades of research are slowly coalescing 
into a unified understanding of how and why β-cells differ. Whether these discoveries will make 
meaningful improvements in the way diabetes is studied and treated remains to be seen. 
1.10 Scope of Thesis 
 Previous work established that obese SM/J mice transition from hyperglycemic at 20 
weeks of age to normoglycemic by 30 weeks of age. Given the importance of β-cell function in  
maintaining glycemic control, we sought to explore how obese SM/J β-cells change during this 
remarkable period. By contrast β-cells in hyperglycemic-obese and normoglycemic-obese mice, 
we aim to identify the genes and pathways associated with improved glucose homeostasis, which 
may reveal novel strategies that improve β-cell function in obesity. Given the increasing 
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relevance of β-cell heterogeneity in diabetes research, we also sought to characterize β-cell 
subpopulations in obese SM/J mice, and how they contribute to the hyper- and normoglycemic-
obese states. By integrating phenotypic information with subpopulation structure, a more 
complete picture of β-cell function in obese SM/J mice can be achieved. The following chapters 
explore how obese SM/J β-cell’s change from a morphological, functional, transcriptional, and 
single cell perspective. 
 In chapter 2 we characterize insulin homeostasis, islet morphology, and β-cell function 
during SM/J’s diabetic remission. Obese SM/J mice dramatically increase circulating and 
pancreatic insulin levels, improve insulin sensitivity, and increase β-cell mass. Functional 
assessment reveals obese SM/J mice increase glucose stimulated insulin secretion, decrease basal 
insulin secretion, and increase islet insulin content.  In chapter 3, we integrate islet single-cell 
and bulk RNA sequencing data. We identify 4 β-cell subpopulations associated with insulin 
secretion, hypoxia response, cell polarity, and stress response are influenced by age, sex, and 
diet. Network analysis identifies fatty acid metabolism gene expression modules associated with 
the hyperglycemic-obese state. We identify Pdyn and Fam151a as candidate regulators of β-cell 
function in obesity. This study establishes that β-cell mass expansion and improved β-cell 
function underlie the resolution of hyperglycemia and uses a novel data integration method to 
explore how β-cells respond to obesity and glycemic stress, helping to define the relationship 






1.11 Figures and Legends 
  
Figure 1.1. Classes, sources, and subtypes of β-cell heterogeneity. β-cells display variation in 
gene expression (red), protein level (blue), morphology (green), and function (purple). 
Heterogeneity is influenced by β-cell source (A), maturation state (B), topology (C), and stress 
response (D). (A) β-cell sources include neogenesis during development, transdifferentiation of 
α- and ductal cells, β-cell replication, and differentiation PMPs. (B) Immature β-cells (B1) and 
mature β-cells (B2) present distinct gene expression, protein, and functional characteristics. (C) 
Topology influences β-cells through the core-mantel structure, where peripheral β-cells (C1) 
have more heterotypic contacts, resulting in low glucose sensitivity and insulin release compared 
to core β-cells (C2). (D) β-cell stress response causes β-cells to cycle between states of high 
insulin with low UPR, low insulin with high UPR, and a period of low insulin with low UPR. 
Two subtypes of adult β-cells have been identified: Hub cells (E1) are characterized by very high 
Gck expression but low insulin expression, and high number of homotypic contacts. Extreme β-
cells (E2) are located near the islet core, characterized by very high insulin expression but low 
mature insulin protein stores. It is unclear if hub cells and extreme β-cells stem from a mature or 
immature population. PMP – Pancreatic multipotent progenitor, INS – Insulin expression, Insulin 





Figure 1.2. Maturation state heterogeneity in pancreatic beta β-cells. (A) Following birth, 
neonatal β-cells are transcriptionally and functionally immature, characterized by Pax6, Hk1, 
Paxa, and Mafb expression, very high proliferation rates, very high basal insulin secretion, and 
high glucose sensitivity. Maturation is facilitated by transition to a carbohydrate rich diet at 
weaning.  (B) Mature β-cells are characterized by expression of Mafa, Ucn3, and Fltp, high 
expression of insulin, Glut2, and Gck. These β-cells have low proliferation rates but high 
glucose-stimulated insulin secretion. A subset of adult β-cells maintain an immature-like profile, 
including Mafb expression, low expression of insulin, Glut2, and Gck, and lack Fltp expression. 
These cells have elevated proliferation rates but low glucose-simulated insulin secretion. 
Whether these cells differ in developmental origin or can interconvert is unknown. (C) In 
diabetes, glucotoxicity, lipotoxicity, and inflammation induces variable fates in β-cells, including 
dedifferentiation, apoptosis, and replication. Dedifferentiated β-cells have expression of 
developmental genes including Ngn3, Oc4, and Nanog, low expression of genes associated with 
mature beta cells including Pdx1, Mafa, Foxo1, and insulin, and low glucose-stimulated insulin 
secretion. Other fates for β-cells in diabetes include replication and apoptosis. The relationship 
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Maintenance of functional β-cell mass is critical to preventing diabetes, but the physiological 
mechanisms that cause β-cell populations to thrive or fail in the context of obesity are unknown. 
High fat-fed SM/J mice spontaneously transition from hyperglycemic-obese to normoglycemic-
obese with age, providing a unique opportunity to study β-cell adaptation. Here, we characterize 
insulin homeostasis, islet morphology, and β-cell function during SM/J’s diabetic remission. As 
they resolve hyperglycemia, obese SM/J mice dramatically increase circulating and pancreatic 
insulin levels while improving insulin sensitivity. Immunostaining of pancreatic sections reveals 
that obese SM/J mice selectively increase β-cell mass but not α-cell mass. Obese SM/J mice do 
not show elevated β-cell mitotic index, but rather elevated α-cell mitotic index. Functional 
assessment of isolated islets reveals that obese SM/J mice increase glucose stimulated insulin 
secretion, decrease basal insulin secretion, and increase islet insulin content. These results 
establish that β-cell mass expansion and improved β-cell function underlie the resolution of 
hyperglycemia, indicating that obese SM/J mice are a valuable tool for exploring how functional 










2.2 Introduction  
Obesity and diabetes are a deadly combination, compounding risk for cardiovascular disease, 
cancer, and stroke265–267. Obesity raises the risk of developing type 2 diabetes 27-76 fold, while 
approximately 60% of individuals with diabetes are obese268–271. Chronic obesity exerts glycemic 
stress on pancreatic β-cells, causing dysregulation and dysfunction, ultimately resulting in 
hyperglycemia272–275. Despite the stress obesity places on β-cells, 10-30% of obese individuals 
maintain glycemic control and are at low risk for developing diabetes276. These low-risk obese 
individuals have elevated β-cell mass and improved insulin secretion compared to BMI-matched 
diabetic-obese individuals2,13,277,278. Understanding the differences in β-cell physiology between 
these populations may reveal therapeutic strategies for maintaining and improving glycemic 
control in obese individuals. 
Recent work suggests β-cells do not respond uniformly to glycemic stress, rather they 
experience variable fates including dedifferentiation, replication, and apoptosis2,27,279. 
Understanding how these changes mediate diabetic risk is complicated by β-cell heterogeneity. 
β-cell populations include subtypes that specialize in basal insulin secretion, β-cell replication, 
coordinating “hub” cells, and β-cells derived from transdifferentiated α-cells, each of which 
differ in glycemic stress response23,25,280. Thus, determining what differentiates nondiabetic-
obese and diabetic-obese populations requires connecting β-cell subtypes to their fate in 
prolonged glycemic stress. 
Like in humans, diabetic risk in obese mice depends on genetic background281–284. Variation 
in β-cell heterogeneity likely underlies variability in islet stress response, and thus needs to be 
accounted for when comparing nondiabetic-obese and diabetic-obese populations. Loss of 
function mutations in leptin (ob/ob) and leptin receptor (db/db) provide insight into β-cell 
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physiology in nondiabetic-obese and diabetic-obese states within individual mouse strains2,285–
288, however leptin and its receptor play a critical role in β-cell function independent of obesity, 
limiting interpretations of these studies289. No current mouse model is well-suited to examine 
physiological differences in β-cell health between nondiabetic-obese and diabetic-obese states. 
The SM/J inbred mouse strain has traditionally been used to study interactions between diet 
and metabolism, and more recently has uncovered genetic architecture underlying diet-induced 
obesity and glucose homeostasis290–295. After 20 weeks on a high fat diet, SM/J mice display 
characteristics of diabetic-obese mice, including elevated adiposity, hyperglycemia, and glucose 
intolerance296. We have previously shown that by 30 weeks of age, high fat-fed SM/J mice enter 
diabetic remission, characterized by normalized fasting blood glucose, and greatly improved 
glucose tolerance and insulin sensitivity297. Importantly, these changes occur in the context of 
sustained obesity. Given the central role of β-cell health in susceptibility to diabetic-obesity, we 
hypothesize that obese SM/J mice undergo restoration of functional β-cell mass during the 
resolution of hyperglycemia. This study focuses on how insulin homeostasis, β-cell morphology, 
and β-cell function change during this remarkable transition and establishes SM/J mice as a 
useful model for teasing apart diabetic-obese and nondiabetic-obese states. 
 
2.3 Methods 
Animal husbandry and tissue collection. SM/J mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). Experimental animals were generated at the Washington University School of 
Medicine and all experiments were approved by the Institutional Animal Care and Use 
Committee in accordance with the National Institutes of Health guidelines for the care and use of 
laboratory animals. Mice were weaned onto a high fat diet (42% kcal from fat; Envigo Teklad 
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TD88137) or an isocaloric low fat diet (15% kcal from fat; Research Diets D12284), as 
previously described297. At 20 or 30 weeks of age, mice were fasted for 4 hours, and blood 
glucose was measured via glucometer (GLUCOCARD). Mice were then injected with an 
overdose of sodium pentobarbital, followed by a toe pinch to ensure unconsciousness. Blood was 
collected via cardiac puncture and pancreas was detached from the spleen and duodenum. 
Serum and pancreatic insulin measurements. Blood obtained via cardiac puncture was spun at 
6000 rpm at 4°C for 20 minutes to separate plasma, which was collected and stored at -80 °C. 
Whole pancreas was homogenized in acid ethanol and incubated at 4°C for 48 hours, shaking. 
Homogenate was centrifuged at 2500 rpm for 30 min at 4°C. Supernatant was collected and 
stored at -20°C. Protein content was measured using Pierce BCA Protein Assay kit (Thermo 
Scientific) according to manufacturer’s instructions and read at 562 nm on the Synergy H1 
Microplate Reader (Biotek). Insulin ELISA (ALPCO 80-INSMR-CH01) was used to measure 
plasma and pancreatic insulin levels following manufacturer’s instructions. 
Insulin Tolerance Test. At 19 or 29 weeks of age, mice were fasted for 4 hours prior to 
procedure. Insulin (humulin) was prepared by mixing 10 ul insulin with 10 ml sterile saline. 
Mice were injected with 3.75 ul insulin mixture/g bodyweight. Blood glucose levels were 
assessed from a tail nick at times = 0, 15, 30, 60, and 120 minutes via glucometer 
(GLUCOCARD). 
Islet Histology and Analyses. At the time of tissue collection, whole pancreas was placed in 3 mL 
of neutral buffered formalin. These samples were incubated at 4°C while gently shaking for 24 
hours. Immediately afterwards, samples were placed into plastic cages and acclimated to 50% 
EtOH for 1 hour. Samples were then processed into paraffin blocks using a Leica tissue 
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processor with the following protocol: 70% EtOH for 1 hour x 2, 85% EtOH for 1 hour, 95% 
EtOH for 1 hour x 2, 100% EtOH for 1 hour x 2, Xylenes for 1 hour x 2, paraffin wax. Pancreas 
blocks were sectioned into 4 μm thick sections. Four samples per individual were randomly 
selected, at least 100 μm apart. 
Slides were incubated at 60°C for 1 hour, then placed in xylenes to remove remaining paraffin 
wax. Slides were then rehydrated using successive decreasing EtOH concentrations (xylenes x 2, 
50% EtOH in xylenes, 100% EtOH x 2, 95% EtOH, 70% EtOH, 50% EtOH, H2O). Slides were 
incubated in sodium citrate (pH 6) at 85°C for 30 minutes, then submerged in running water for 
5 minutes. Slides were washed with 0.025% Triton X-100 in TBS and blocked in 10% normal 
donkey serum for 1 hour (Abcam ab7475), followed by incubation with primary antibody 
overnight at 4°C. [Primary antibodies: rat anti-insulin (1:100, R&D MAB1417), mouse anti-
glucagon (1:100, Abcam ab10988), and rabbit anti-phospho-histone H3 (1:100, Sigma 
SAB4504429)]. After an additional wash, secondary antibody was applied for 1 hour at room 
temperature. [Secondary antibodies: donkey anti-rabbit 488 (1:1000, Abcam ab150061), donkey 
anti-mouse 647 (1:1000, Abcam ab150107), and donkey anti-rat 555 (1:1000, Abcam ab 
150154)]. Fluoroshield Mounting Medium with DAPI (Abcam) was applied to seal the coverslip 
and slides were stored at 4°C. Imaging was performed using the Zeiss AxioScan .Z1 at 20X 
magnification and 94.79% laser intensity. 
Background was subtracted from DAPI, insulin, glucagon, and phospho-histone H3 images using 
ImageJ. DAPI channel was used to identify total nuclei in CellProfiler. Insulin and glucagon 
channels were combined and overlaid on the DAPI image to identify islet nuclei. Insulin (INS+) 
staining overlaid with DAPI identified β-cell cells, glucagon (GCG+) staining overlaid with 
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DAPI identified α-cells, based on the proximity of the signal to a given nuclei. Phosphohistone 
H3 (PHH3+) staining identified mitotic nuclei. Total nuclei, islet cells, β-cells, α-cells, and 
mitotic nuclei were summed across 4 slides for each individual. Islet, β-cell, and α-cell mass is 
reported as fraction of total nuclei. Mitotic islet index is reported as proportion of β-cells and α-
cells positive for phosphohistone H3. Mean β-cell area was calculated by dividing the total INS+ 
area by the number of INS+ cells. Mean β-cell area is reported for each individual. Islets with 
diameter < 50 µm were discarded. 
Islet isolation. Pancreas was removed and placed in 8mL HBSS buffer on ice. Pancreas was then 
thoroughly minced. Collagenase P (Roche) was added to a final concentration of 0.75 mg/ml. 
Mixture was then shaken in a 37°C water bath for 10-14 minutes. Mixture was spun at 1500 rpm 
for 2 minutes. The pellet was washed twice with HBSS. The pellet was re-suspended in HBSS 
and transferred a petri dish. Hand-selected islets were placed in sterile-filtered RPMI with L-
glutamine (Gibco) containing 11mM glucose, supplemented with 5% pen/strep and 10% Fetal 
Bovine Serum (Gibco). Islets were rested overnight in a cell culture incubator set to 37°C with 
5% CO2. 
Glucose Stimulated Insulin Secretion and Islet Insulin Content. Islets of roughly equal size were 
equilibrated in KRBH buffer containing 2.8 mM glucose for 30 minutes at 37°C. 5 islets were 
hand selected and placed in 150 µl KRBH containing either 2.8 or 11 mM glucose. Tubes were 
placed in a 37°C water bath for 45 min. Islets were then spun at 2000 x g, hand-picked with a 
pipette, and transferred from the secretion tube and placed in the content tube with acid ethanol. 
The content and secretion tubes were stored at -20°C overnight. Each condition was performed 
in duplicate for each individual. Mouse insulin ELISA (ALPCO 80-INSMU-E01) was performed 
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according to manufacturer’s instructions, with the secretion tubes diluted 1:5, and content tubes 
diluted 1:100. Normalized insulin secretion was calculated by dividing the secreted value by the 
content value. Glucose stimulated insulin secretion was calculated by dividing the normalized 
insulin secretion at 11mM glucose by the normalized insulin secretion at 2.8 mM glucose. Each 
sample was measured in duplicate. Total islet protein within each content tube was measured 
using Pierce BCA Protein Assay kit (Thermo Scientific) according to manufacturer’s instructions 
and read at 562 nm on the Synergy H1 Microplate Reader (Biotek). Islet insulin content was 
calculated by dividing the insulin level in the content tubes by the total protein value. 
Statistical analyses. Phenotypes were assessed for normality by a Shapiro-Wilk test, and outliers 
removed. ANOVA revealed that sex-by-diet-by-age interactions did not contribute meaningful 
variance to any phenotype so males and females were pooled at each time point. A student’s t-
test was used to assess significance between two cohorts, while a one-way ANOVA with 
Tukey’s Post Hoc test was used to assess significance among multiple cohorts. Pearson’s 
correlation was used to determine strength of correlation among variables. P-values < 0.05 were 
considered significant.  
 
2.4 Results 
Obese SM/J mice increase insulin levels and improve insulin sensitivity. The resiliency of β-cells 
distinguishes nondiabetic-obese and diabetic-obese individuals287,288,298–303. While both groups 
develop hyperinsulinemia, diabetic-obese individuals become insulin resistant, leading to β-cell 
dysfunction, hypoinsulinemia, and hyperglycemia. Our previous work shows that obese SM/J 
mice spontaneously transition from hyperglycemic to normoglycemic with age297. Principle to 
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this is a 40 mg/dl decrease in fasting glucose levels in high fat-fed SM/J mice between 20 and 
30-weeks (Figure 2.1A). We first sought to characterize how insulin homeostasis changes during 
this transition. Interestingly, 20-week high fat-fed SM/J mice have comparable levels of plasma 
and pancreatic insulin levels compared to age-matched low fat-fed mice (Figure 2.1B-C). By 30 
weeks, high fat-fed SM/J mice increase circulating insulin levels 5.3-fold and pancreatic insulin 
levels 1.9-fold, in line with other models of hyperinsulinimic nondiabetic-obesity304–306. We 
sought to test for peripheral insulin resistance via an insulin tolerance test (ITT), as insulin 
resistance is a known mechanism for increasing circulating and pancreatic insulin levels. 
Surprisingly, 20-week high fat-fed SM/J mice display insulin resistance compared to low fat-fed 
mice, however, insulin sensitivity is restored by 30 weeks (Figure 2.1D-E). The simultaneous 
increase in insulin production and improved insulin sensitivity is unprecedented and suggests a 
novel mechanism beyond insulin resistance for enhancing β-cell insulin secretion.  
 
Obese SM/J mice increase islet mass during resolution of hyperglycemia. In humans and mice, 
obesity initially increases islet mass, and maintenance of that mass in part differentiates 
nondiabetic-obese individuals from diabetic-obese individuals2,13,47,277,307,308. To understand the 
source of increased insulin production in obese SM/J mice, we examined islet morphology 
during the resolution of hyperglycemia. To quantify islet mass and number, β-cell mass, α-cell 
mass, and mitotic index, we randomly selected 4 sections per fixed pancreas and stained with 
antibodies against insulin, glucagon, and phospho-histone H3. Representative images of 
immuno-stained pancreatic sections for 30-week high fat-fed mice and 30-week low fat-fed mice 
are shown in Figure 2.2A-B. Consistent with other mouse models of obesity, 20-week high fat-
fed SM/J mice have a 2.75-fold increase in total islet mass compared to low fat-fed mice (Figure 
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2.2C). This increased mass is driven by an increase in both median islet area and number of 
islets (Figure 2.2D-E). Islet mass is further elevated 2-fold between 20- and 30-weeks in high 
fat-fed mice, while the islet population remains unchanged in low fat-fed mice. A full summary 
of the islet quantification is presented in Table 2.1. Distribution of islet size is shown in Figure 
2.5, along with corresponding density plot for each cohort. Islet mass correlates with BMI in 
obese humans309, a similar correlation is seen between islet mass and body weight in high fat-fed 
SM/J mice (Fig. 2F). 
 
Obese SM/J mice increase β-cell mass and α-cell replication. To identify the source of the 
increased islet mass in high fat-fed SM/J mice, we quantified the relative representation of β-
cells and α-cells within each cohort. Increased islet mass in 20-week high fat-fed mice is driven 
by a 3.3-fold increase in the number of β-cells and a 2.5-fold increase in the number of α-cells 
compared to low fat mice, while growth between 20- and 30-week high fat-fed mice is driven by 
a further 2.2-fold increase in β-cell number (Figure 2.3A-B). In obesity, islet mass expands 
primarily through β-cell hyperplasia15,27,47,310. Mean β-cell area is not different across age and 
dietary cohorts (Figure 2.6) We quantified mitotic index of β- and α-cells in our model using 
phosphohistone H3 and assessed how mitotic index relates to β-cell mass during the resolution of 
hyperglycemia in obese SM/J mice. Surprisingly, calculation of β-cell mitotic index reveals 
similar rates of β-cell replication across cohorts (Figure 2.3C), while α-cell mitotic index is 
elevated 6-fold in high fat-fed mice compared to low fat-fed controls (Figure 2.3D). Examining 
the relationship between β-cell mitotic index and β-cell mass in high fat-fed mice reveals β-cell 




Obese SM/J mice increase islet insulin secretion and insulin content. In conjunction with 
changing β-cell morphology, diabetic-obesity is associated with altered β-cell function, including 
diminished first phase insulin secretion, increased basal insulin secretion, and decreased β-cell 
insulin production(12, 17, 50, 60). We sought to examine if changes in β-cell insulin secretion 
and content corresponded with the resolution of hyperglycemia and expanded β-cell mass we 
observe. To test this, we isolated islets from high and low fat-fed 20- and 30-week SM/J mice. 
After allowing islets to rest overnight, we performed a glucose-stimulated insulin secretion assay 
by subjecting islets to low (2.8 mM) or high (11 mM) glucose conditions. We find that high fat-
fed SM/J mice dramatically improve glucose-stimulated insulin secretion between 20 and 30 
weeks of age. This includes transitioning from blunted insulin secretion under high glucose 
conditions to appropriately elevated secretion (Figure 2.4A), and improvement in the ratio of 
insulin secreted in response to high vs low glucose conditions (Figure 2.4B). Normalized insulin 
secreted in response to elevated glucose does not differ between cohorts (Figure 2.6A). 20-week 
high fat-fed mice have elevated insulin secretion in response to low glucose (Fig. 4C), consistent 
with other studies of islets in type 2 diabetic humans and mice. Correspondingly, 20-week high 
fat-fed SM/J mice have decreased islet insulin content (Figure 2.4D), which increases 3-fold by 
30 weeks. Consistent with current understanding of the β-cell maturation process311, there is a 
positive correlation between islet insulin content and glucose-stimulated insulin secretion in high 
fat-fed (Figure 2.4E) and low fat-fed (Figure 2.6B) SM/J mice. This suggests that obese SM/J 
mice experience β-cell maturation between 20 and 30 weeks, characterized by increased insulin 
content and improved insulin secretion in response to high glucose. This spontaneous 
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improvement in β-cell health and function in the context of obesity has not been reported in other 
mouse strains, suggesting a genetic basis unique to SM/J. 
 
2.5 Discussion 
The ability to maintain appropriate insulin production and secretion, termed functional β-
cell mass, is a central determinant of diabetic risk. In this study, we describe insulin homeostasis, 
islet morphology, and β-cell function in obese SM/J mice as they transition from hyperglycemic 
to normoglycemic. We determine that increased insulin production and insulin sensitivity 
accompany improved glycemic control, driven by expanded β-cell mass and improved glucose-
stimulated insulin secretion. Our results show obese SM/J mice undergo restoration of functional 
β-cell mass, providing an opportunity to explore how compensatory insulin production can be 
achieved in the context of obesity. 
Susceptibility to high fat diet-induced diabetes in mice depends on genetic background. 
Several strains and sub-strains develop diabetic-obesity, including hyperglycemia, glucose 
intolerance, and insulin resistance, consistent with the diabetic phenotypes observed in obese 
SM/J mice at 20 weeks281,312,313. Remarkably, by 30 weeks, obese SM/J mice have characteristics 
of diabetic-resistant obese strains, retaining glycemic control by dramatically increasing insulin 
production and improving insulin sensitivity282,284,312,313. To our knowledge, this is the first report 
of transient hyperglycemia in an inbred strain, although similar phenomena have been reported in 
mice with the leptin receptor (db/db) mutation. C57bl/6J (db/db) and 129/J (db/db) mice are obese and 
initially develop mild hyperglycemia at 8-10 weeks of age, but this resolves by 20-30 weeks, 
concurrent with increased insulin production and β-cell mass285,286. Unfortunately, leptin and its 
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receptor play an important role in β-cell growth and function independent of obesity, which 
confounds understanding of how genetic background mediates diabetic risk in obesity289. 
Interestingly, low fat fed mice increase circulating insulin levels between 20- and 30-weeks, 
despite no change in pancreatic insulin levels, insulin sensitivity, or β-cell mass. 
 High fat diet-induced obesity in mice can result in increased islet mass, no change, or 
decreased mass282,284,313–315. Across these studies, inability to expand islet mass is associated with 
hyperglycemia. In humans, islet mass correlates with BMI in nondiabetic obese-individuals, 
while diabetic-obese individuals have low islet mass compared to nondiabetic 
individuals300,309,316. High fat-fed SM/J mice are unique because they have expanded islet mass at 
20 weeks, yet normal insulin levels and insulin resistance. By 30-weeks, islet mass continues to 
expand, driven by increased islet area and increased islet number, corresponding with increased 
insulin production and improved insulin sensitivity. Islet neogenesis may contribute to the 
increased islet number, and fission of large islets has been reported during development, 
suggesting islets have mechanisms to maintain an appropriate size317,318.  
β-cell hyperplasia is the primary driver of islet expansion in mouse models of 
obesity287,288. Some nondiabetic obese mice experience increased β-cell number, but do not show 
evidence for elevated β-cell replication in immunostaining of pancreatic sections282,315. This has 
been attributed to islets in the tail of the pancreas being substantially more proliferative in 
response to high fat diet than the body and head regions118, thus technical artifacts in sampling 
could result in inflated variances which mask biological differences. This could be the case here, 
given that high fat-fed SM/J’s β-cell number is far above low fat-fed controls, that their β-cell 
number expands 2-fold during the resolution of hyperglycemia, yet we find no evidence for 
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increased β-cell replication. However, α-cell number also expands in obesity319–321. While α-cell 
mass is elevated in high fat-fed SM/J mice compared to low fat-fed controls, we find it does not 
change between 20 and 30 weeks, despite substantial elevation of α-cell mitotic index.  
Retention of β-cell function separates diabetic-obesity and nondiabetic obesity322–324. 20-
week high fat-fed SM/J mice have an insulin secretion profile similar to diabetic-obese mice and 
humans, including blunted glucose-stimulate insulin release, elevated basal insulin secretion, and 
low islet insulin content, which resolves by 30 weeks. Underscoring this transition is the positive 
correlation between glucose-stimulated insulin release and islet insulin content. Care was taken 
to select normal sized islets across all cohorts for functional assessment (~100µm in diameter) 
indicating this robust improvement in β-cell functional mass is due to changes to β-cell 
physiology. 
Three current, non-mutually exclusive components of β-cell stress response may shed 
light on the perplexing improvement in glycemic control seen in SM/J mice: β-cell 
dedifferentiation, nascent β-cell maturation, and changes in β-cell subtype proportions. While 
early studies concluded overworked β-cells undergo apoptosis2,325–327, recent studies have 
suggested β-cells dedifferentiate into a dysfunctional, progenitor-like state, potentially as a 
defense mechanisms against prolonged glycemic stress236,279,328,329. These dedifferentiated β-cells 
have low insulin content and poor glucose-stimulated insulin secretion. Further, the 
dedifferentiated state is reversible in cultured conditions, revealing potential for therapeutic 
intervention239. It is feasible that obese SM/J mice have β-cells in the dedifferentiated state at 20-
weeks, which would explain the low insulin content and poor functionality despite the elevated 
β-cell mass. Improvement in insulin sensitivity could ease glycemic stress, allowing 
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dedifferentiated β-cells to redifferentiate by 30 weeks, reestablishing insulin production and 
secretion.  
Work from several groups suggests β-cells can be divided into two broad categories: 
functionally immature and functionally mature cells. Immature β-cells have greater proliferative 
potential and are resistant to stress, at the expense of functional maturity45,218,330. These immature 
β-cells have low insulin content, high basal insulin secretion, and a lack of glucose stimulated 
insulin secretion. The large β-cell expansion seen in obese SM/J mice, suggests nascent β-cells 
must undergo maturation at some point. We have no evidence of enhanced β-cell replication at 
20-weeks, but it is possible these β-cell are still functionally immature and reach maturity by 30-
weeks. This could explain why islets from these mice lack glucose stimulated insulin release, 
show elevated basal insulin secretion, and have low insulin content, despite elevated mass.  
Recent advances in single cell technology allows for identification of β-cell subtypes, 
based on functional characteristics and gene expression. These include β-cells that specializes in 
basal insulin secretion, characterized by low mature insulin content, and enriched in db/db 
diabetic islets23. While these cells are not equipped to respond to elevated glucose, they are 
enriched for maturity markers including Ucn3 and Glut2, distinguishing them from immature β-
cells. Pancreatic multipotent progenitors (PMPs) are rare insulin positive cells capable of 
generating endocrine cells in vivo including functionally mature β-cells25,194. These cells 
resemble immature β-cells, with low insulin content and Glut2 expression, whose proliferation is 
stimulated by glycemic stress in STZ-treated and NOD mouse models. Lastly, β-cell hub cells 
coordinate calcium signaling and insulin release of surrounding β-cells280. These cells have 
markers for both mature and immature β-cells, including expression of Gck and Pdx1, but low 
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insulin content, and are especially sensitive to glycemic and inflammatory stress. Ablation of 
these cells results in loss of coordinated insulin release, suggesting they are necessary for mature 
islet function. Given the elevated β-cell mass, poor insulin secretion, and low insulin content in 
20-week high fat-fed SM/J mice, it is possible islets are enriched for basal insulin secretors and 
PMP’s, while devoid of hub cells. At 30 weeks, as glycemic stress diminishes, basal insulin 
secretors and PMP populations decline, while hub cells rise, reestablishing β-cell functionality.  
Clearly, the interplay between β-cell dedifferentiation, nascent β-cell maturation, and β-
cell subtype identity in diabetic-obesity needs to be clarified. SM/J mice are a useful model 
because they allow for appropriate comparisons across diabetic-obese, nondiabetic-obese, and 
nondiabetic-lean populations. The improvement in β-cell function and increase in insulin 
production in obese SM/J mice could be explained by a combination of these innate and stress 
response β-cell mechanisms. Future studies interrogating how SM/J β-cells change over time will 
provide insight into the physiological mechanisms that allow β-cell functionality to be 









2.6 Figures and Legends 
 
Figure 2.1. Insulin homeostasis during the resolution of hyperglycemia in obese SM/J mice. 
Blood glucose levels measured after 4-hour fast from high and low fat-fed, 20- and 30-week 
SM/J mice (A). Plasma insulin (B) and pancreatic insulin levels (C) assessed via insulin ELISA, 
collected after 4-hour fast. Insulin tolerance test performed via intraperitoneal insulin injection 
following 4-hour fast (D), summarized in the area under the curve (E). N = 38-50 mice per 
cohort for panel A, C, D. N = 10-24 mice per cohort for panel B-C, equal numbers of males and 
females. Bar represents group means, error bars represent SEM. *p<0.05, **p<0.01, 




Figure 2.2. Changes in islet mass during the resolution of hyperglycemia. Representative 
pancreatic cross sections from 30-week high fat-fed mice (A) and 30-week low fat-fed mice (B) 
stained for insulin (green), glucagon (white), and phosphohistone H3 (red). Dashed white box 
identifies location of image in inset. Solid yellow arrows within inset identify INS+:PHH3+ cells, 
dashed yellow arrow identifies GCG+:PHH3+ cell. Islet mass reported as ratio of islet cells over 
total cells, summed across 4 pancreatic sections (C). Median islet area calculated for each 
individual across 4 sections (D). Total number of islets quantified per individual, normalized by 
total DAPI area (E). Correlation between body weight and β-cell mass in high fat-fed mice (F), 
open circles – 20-week high fat-fed, filled circles – 30-week high fat-fed. N = 12-16 mice per 





Figure 2.3. Islet cell mass and mitotic index in obese SM/J mice. β-cell mass reported as ratio of 
INS+ cells divided by total cells summed across 4 slides per individual (A). α-cell mass reported 
as GCG+ cells divided by total cells summed across 4 slides per individual (B). β-cell mitotic 
index calculated by dividing INS+:PHH3+ cells divided by total INS+ cells summed across 4 
slides per individual (C). α-cell mitotic index calculated by dividing GCG+:PHH3+ cells by total 
GCG+ cells summed across 4 slides (D). Correlation between β-cell mitotic index and β-cell 
mass in 20 week high fat-fed mice (E) and 30-week high fat-fed mice (F). Open circles – 20-
week high fat-fed, filled circles – 30-week high fat-fed. N = 12-16 mice per cohort for all panels, 




Figure 2.4. Islet insulin secretion and insulin content. Islet insulin secretion in response to low 
(2.8 mM) and high (11mM) glucose conditions, normalized by islet insulin content (A), reported 
as a ratio of high glucose to low glucose insulin secretion (B). Comparison of islet insulin 
secretion under low glucose conditions in 20- and 30-week, high and low fat-fed mice (C). Islet 
insulin content normalized by total protein measured via protein BCA (D). Correlation between 
insulin secretion ratio and islet insulin content (E). Open circles – 20-week high fat-fed, closed 
circles – 30-week high fat-fed. N = 8-19 mice per cohort for panels A-C, n = 5-11 mice per 





Figure 2.5. Islet area histogram (left) and density plot (right) for each cohort, 20-week high fat 
(A), 30-week high fat (B), 20-week low fat (C), and 30-week low fat (D). Dashed line shows 




Figure 2.6. Mean β-cell area per individual. Total INS+ area divided by total INS+ cells, summed 






Figure 2.7. Normalized insulin secretion in response to elevated (11 mM) glucose (A). Islet 
insulin content vs glucose-stimulated insulin secretion for low fat-fed mice (B). A, N =5-14 







Table 2.1. Cohort metrics for islet mass quantification. 
Cohort 20 HF 30 HF 20 LF 30 LF
Individuals 16 16 12 11
Female /Male Ratio 0.5 0.5 0.5 0.64
Slides 62 64 48 40
Total Islets 8,320 10,380 2,333 3,141
Total Islet Area (µm²) 132,564,412 194,565,474 19,956,617 28,581,981
Avg Iset Area (µm²) 15,933 18,744 8,554 9,100
Islets/Slide 134.2 162.2 48.6 78.5
Area/Slide 2,138,136 3,040,086 415,763 714,550
Total Tissue Area (µm²) 496,461,183 512,715,812 176,863,435 198,371,139
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Understanding how heterogeneous β-cell function and stress response impact diabetic etiology is 
imperative for therapy development. Standard single-cell RNA sequencing analysis illuminates 
some genetic underpinnings driving heterogeneity, but new strategies are required to capture 
information lost due to technical limitations. Here, we integrate pancreatic islet single-cell and 
bulk RNA sequencing data to identify β-cell subpopulations based on gene expression and 
characterize genetic networks associated with β-cell function in high- and low-fat fed male and 
female SM/J mice at 20 and 30wks of age. Previous studies have shown that high-fat fed SM/J 
mice resolve glycemic dysfunction between 20 and 30wks.  We identify 4 β-cell subpopulations 
associated with insulin secretion, hypoxia response, cell polarity, and stress response. Relative 
proportions of these cells are influenced by age, sex, and diet. Network analysis identifies fatty 
acid metabolism and β-cell physiology gene expression modules associated with the 
hyperglycemic-obese state. We identify subtype-specific expression of Pdyn and Fam151a as 
candidate regulators of genetic pathways associated with β-cell function in obesity. In sum, this 
study uses a novel data integration method to explore how β-cells respond to obesity and 
glycemic stress, helping to define the relationship between β-cell heterogeneity and diabetes, and 










Proper insulin secretion from pancreatic β-cells is required to maintain glycemic control. 
Obesity initially promotes β-cell expansion, but prolonged glycemic stress and inflammation 
drive β-cell death and dysfunction, resulting in type 2 diabetes2,3,241. Without sufficient β-cell 
mass and insulin production, sustained hyperglycemia increases risk for deadly metabolic 
diseases331–333. Currently, transplantation of cadaveric islets is the only method for restoring β-
cell mass in diabetes but is severely limited by donor availability and requires lifelong 
immunosuppressant therapy334,335. Differentiating induced pluripotent stem cells into insulin 
secreting cells may alleviate this bottleneck, but current methods fail to recapitulate fine-tuned 
glucose sensing and insulin secretion in vivo336,337. There is urgent need for therapies that 
improve endogenous β-cell function. This requires understanding how and why β-cells become 
dysfunctional in obesity. 
Improving endogenous β-cell function in diabetes is complicated by cellular 
heterogeneity, because individual β-cells vary significantly in function, gene expression, protein 
level, and stress response338. Single cell technologies permit interrogation of the molecular 
underpinnings of heterogeneity, addressing two fundamental questions: Do functionally distinct 
subpopulations of β-cells exist? Can accounting for heterogeneity improve diabetic therapy? 
Several research groups have proposed subpopulations based on clustering analysis using single 
cell RNA sequencing (scRNA-seq), however, there is little agreement among studies21,90,91,339. 
High rates of gene dropout and low read depth contribute to these problems, necessitating 
approaches that improve information capture without losing cell type-specific information102,104. 
Integrating sc-RNAseq with bulk RNAseq data leverages bulk sequencing’s high read 
depth, allowing for capture of lowly expressed genes and robust expression analysis. Several 
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tools can integrate sc- and bulk RNA-seq data, focusing on deconvoluting bulk RNAseq data 
from heterogeneous tissue to account for differences in tissue composition90,340,341. These 
methods estimate and control for cell type abundance but do not identify cell type-specific 
expression signatures in bulk datasets. Analytical strategies that identify cellular gene expression 
signatures in bulk RNAseq data allow for robust cell type-specific differential expression 
analysis and complex network analysis that is currently not feasible in scRNA-seq data. 
Here, we characterize gene expression in β-cells from obese SM/J mice, who 
spontaneously transition from hyperglycemic to normoglycemic with improved β-cell function 
between 20 and 30 weeks of age342,343. We assign functional identities to 4 subpopulations of β-
cells using scRNA-seq. These subpopulations vary in proportion among hyperglycemic-obese, 
normoglycemic-obese, and normoglycemic-lean mice. We identify 316 genes specifically 
expressed by β-cells and establish a β-cell gene expression profile for each mouse. We leverage 
this information to focus our analyses of bulk-islet RNAseq and identify β-cell-specific 
differential expression and gene networks associated with the hyperglycemic-obese, 
normoglycemic-obese, and normoglycemic-lean states. Two novel potential regulators of β-cell 
function, Pdyn (Prodynorphin) and Fam151a (Family with sequence similarity 151 member A), 
are differentially expressed, highly connected within genetic networks, and primarily expressed 
by β-cell subpopulations associated with normoglycemia. This analysis demonstrates that 
integrating scRNAseq with bulk RNAseq is a powerful approach for exploring β-cell 
heterogeneity and identifying key genes and subpopulations that strongly associate with 
glycemic state. The genetic networks and β-cell subpopulation signatures we identify have high 





Metabolic phenotyping. SM/J mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME). Mouse colony was maintained at the Washington University School of Medicine and all 
experiments were approved by the Institutional Animal Care and Use Committee in accordance 
with the National Institutes of Health guidelines for the care and use of laboratory animals. Mice 
were weaned onto a high-fat diet (42% kcal from fat; Envigo Teklad TD88137) or isocaloric 
low-fat diet (15% kcal from fat; Research Diets D12284), as previously described343. At 20 or 30 
weeks of age, mice were fasted for 4 hours, body weight measured, and blood glucose was 
measured via glucometer (GLUCOCARD). Mice were injected with sodium pentobarbital, 
followed by a firm toe pinch to ensure unconsciousness. Blood was collected via cardiac 
puncture and pancreas was collected. Blood was spun at 6000 rpm at 4°C for 20 minutes to 
collect plasma. Insulin ELISA (ALPCO 80-INSMR-CH01) was used to measure plasma insulin 
levels following manufacturer’s instructions. 
Islet isolation and phenotyping. Islets were isolated from pancreas as previously described342 and 
rested overnight. 5 Islets were equilibrated in KRBH buffer with 2.8 mM glucose for 30 minutes 
at 37°C, then placed in 150 µl KRBH containing 2.8 mM glucose at 37°C for 45 minutes, then 
150 µl KRBH containing 11 mM glucose at 37°C for 45 minutes. Islets were then transferred 
into 150 µl acid ethanol. Islet content and secretion tubes were stored at -20°C overnight. 
Experiments were performed in duplicate per individual, and measurements are reported as the 
average of replicates. Mouse insulin ELISA (ALPCO 80-INSMU-E01) was performed, with the 
secretion tubes diluted 1:5, and content tubes diluted 1:100. Glucose stimulated insulin secretion 
was calculated by dividing insulin secretion at 11mM glucose by insulin secretion at 2.8 mM 
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glucose. Basal insulin secretion was calculated by dividing insulin secretion at 2.8 mM glucose 
by islet insulin content. Total islet protein was measured using Pierce BCA Protein Assay kit 
(Thermo Scientific) according to manufacturer’s instructions and read at 562 nm on the Synergy 
H1 Microplate Reader (Biotek). Islet insulin content was calculated by dividing the islet insulin 
level in the content tubes by total islet protein. All measurements were taken in duplicate, values 
reported are the average of replicates. 
Single cell RNA sequencing. Single cell RNA sequencing (scRNA-seq) was performed on islets 
isolated from 15 SM/J mice representing 6 cohorts: 20wk high-fat females (n=3), 20wk high-fat 
males (n=3), 30wk high-fat females (n=3), 30wk high-fat males (n=2), 20wk low-fat females 
(n=2), and 20wk low-fat males (n=2). Isolated islets were dissociated into single cell suspensions 
using Accumax cell/tissue dissociation solution (Innovative Cell Technologies). Libraries were 
prepped using the Chromium Single Cell 3ʹ GEM, Library & Gel Bead Kit v3 (10xGenomics) 
and sequenced at 2x150 paired end reads using a NovaSeq S4. After sequencing, reads were de-
multiplexed and assigned to individual samples. Reads were aligned using 10x Genomics 
CellRanger (3.1.0) against our custom SM/J reference295. Samples that were prepped together 
were aggregated into batches using CellRanger aggregate. In the R environment (4.0.0), each 
aggregated batch was run through SoupX (1.5.0)344 to estimate and correct for ambient RNA 
contamination. A contamination fraction of 0.05 was chosen. Removal of Ins2 ambient RNA 
shown in Figure 3.8D-E. Adjusted counts were imported into Seurat (3.2.2)345, where cells were 
filtered for number of features detected (500-3000), total counts detected (1000-30000), percent 
mitochondrial genes (0-30), visualized in Figure 3.8A. For additional quality control, we 
excluded cells where nCount was not predictive of nFeature; the predictive error (residual) of a 
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cell had to be within 3 standard deviations of the mean predictive error (~0). Cell counts for 
samples from one batch shown before and after filtering step shown in Figure 3.8B-C. 
Expression was then normalized in Seurat (normalization.method = LogNormalize), batches 
were integrated, and clustered using a shared nearest neighbor approach. Using the top 10 
principal components of the filtered expression data and a resolution of 0.14, we identified 9 
clusters of cells using Clustree (0.4.3)346. Cell types were assigned by identifying top over-
expressed genes for each cluster relative to all other clusters using a Wilcoxon rank sum test, 
with an average log-fold-change threshold of >=0.25 and requiring at least 25% of cells express 
the gene. Identities were assigned by comparing top over-expressed genes for each cluster with 
known cell-type specific markers for islet cells. 
Identification of β-cell subtypes, differential expression, and composition. All β-cells were subset 
for further analysis. Using the top 10 principal components of the filtered expression data and a 
resolution of 0.09 (Figure 3.8F), we identified 4 populations of β-cells, labeled Beta 1-4. Top 
over expressed genes for each population were identified using a Wilcoxon rank sum test, with 
an average log-fold-change threshold >= 0.1 compared to all other β-cells and an adjusted p-
value < 0.01 (Bonferroni). Subtype-identifier genes were tested for gene set enrichment (see 
below) to determine presumed function of each population. Using these thresholds (average log-
fold-change >= 0.1 and adjusted p-value < 0.01), differential expression was calculated between 
pairs of β-cell subpopulations, across all β-cells between 20wk high-fat males and 30wk high-fat 
males, across all β-cells between 20wk high-fat males and 20wk low-fat males, and across Beta 1 
cells between 20wk high-fat males and 20wk low-fat males using the “MAST” hurdle-model 
test347. Relative proportions of β-cell subpopulations in each cohort were estimated using 
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bootstrapping to calculate 95% confidence intervals by randomly sampling 1,000 cells from each 
cohort for 100 iterations. 
Identification of β-cell-specific genes. To identify β-cell-specific gene expression signatures in 
the bulk sequencing data, we assume that for a given gene, the sum of expression in the scRNA-
seq data, YTotal, approximates the expression in bulk RNA sequencing data, YBulk. 
 
The YTotal value can be re-written as the sum of expression from all the contributing cell types, 
where Y is the expression from a given cell type, and N is the total number of cells of that type. 
+ … +  
Therefore, the expected relative contribution of β-cells (Qβ-cell),  to total expression (YTotal),  can 
be written as: 
 
When Qβ-cell is high in all 6 cohorts, we are confident that gene expression in the bulk data is 
nearly exclusively coming from β-cells. To determine the contribution of β-cells and all other 
cell types to gene expression, the distribution of normalized expression was assessed using a 
Cullen and Frey graph using the fitditrplus package (1.1-3)348 in R and identified as beta 
distributed (Figure 3.9A-B). 
scRNA-seq data is characterized by a buildup of expression values at 0 due to cells that 
do not express a gene or due to gene-dropout. This distribution required us to employ a beta-
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hurdle model described by three parameters: Pr(Dropout), α, and β. We treat the probability of 
attaining an expression value of 0 ( Pr(Dropout) ) and the distribution of non-zero values 
separately for a given gene. We fit the expression of each gene in each cell type using a beta-
hurdle model optimized by maximum goodness of fit estimation. To fit the first part of the beta-
hurdle mode, the Kolmogorov-Smirnov statistic using the ks.test package (4.05)349 in R was used 
to select the optimal α and β shape parameters that best fit the expression distribution of non-
zero-expressing cells by minimizing the distance between the cumulative distribution of the real 
data and theoretical beta model data (Ks) (Figure 3.9C). To fit the second part of the beta-hurdle 
mode, Pr(Dropout) was iterated between 0 and 1, selecting the Pr(Dropout) that minimized Ks 
(Figure 3.9D). In most cases, assuming 100% of cells not expressing the gene was due to gene 
drop out provided the best fit (Figure 3.9E). From the best fit beta-hurdle model, the expected 
value for each gene within a cell type  can be calculated using the fit α and β shape 
parameters as: 
 
Multiplying the expected value by the total number of cells of that cell type provides the total 
expression contribution of that cell type. Summing this value across all cell types provides total 
expression and allows assessment of the contribution of β-cell gene expression to the genes’ total 
expression. We required β-cells to account for >=80% of total gene expression in each of the six 
cohorts analyzed, resulting in 316 “β-cell-specific genes”, shown in Table 3.2.  
Bulk RNA sequencing. Islets from 32 mice were sequenced: 4 males and 4 females from each 
diet (high-fat and low-fat) and each age (20wk and 30wk), n=32. Islet RNA was extracted using 
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the RNeasy MinElute Cleanup kit (Qiagen), RNA concentration was measured via Nanodrop and 
RNA quality/integrity was assessed with a BioAnalyzer (Agilent). Libraries were prepped using 
the SMARTer cDNA synthesis kit (Takara Bio) and sequenced at 2x150 paired end reads using a 
NovaSeq S4. After sequencing, reads were de-multiplexed and assigned to individual samples. 
FASTQ files were trimmed and filtered to remove low quality reads and aligned against a SM/J 
custom genome using STAR295,350,351. Read counts for β-cell-specific genes were normalized via 
TMM normalization and pairwise differential expression between cohorts was performed using 
edgeR352. 
Co-expression network analysis. Weighted Gene Co-Expression Network Analysis (WGCNA) 
identifies co-expression modules and correlates them with phenotypic traits353. Briefly, edgeR-
normalized counts for β-cell-specific genes were converted to standard normal, and an adjacency 
matrix was created from bi-weight mid-correlations calculated between all genes in all 
individuals and raised to a power β of 8, chosen based on a scale-free topology index above 0.9, 
to emphasize high correlations354. The blockwiseModules function created an unsigned 
Topological Overlap Measure using the adjacency matrix to identify modules of highly 
interconnected genes. Eigengenes were calculated as the first principal component for each 
module, and Pearson’s correlations were calculated between eigengene expression and 
phenotype to estimate module-trait relationships. Module-trait correlations were considered 
significant at an FDR-corrected p-value < 0.05. The adjacency matrix was then used to calculate 
the connectivity of each gene with other genes within its module (kwithin). Adjacency matrices 
were subset for each age x diet x sex cohort, used to calculate cohort-specific connectivity for 
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each gene, then used to calculate differential connectivity between cohorts. We report differential 
connectivity between 20wk high-fat males and 30wk high-fat males, HM, calculated as 
 
and differential connectivity between 20wk high-fat males and 20wk low-fat males, M20,  
calculated as  
 
 where HM20, HM30, and LM20 are cohort-specific kwithin values for each gene. This provides 
each gene in the comparison with a value between -1 and 1, where |kDiff| > 0.5 is considered 
differentially connected. Genes with positive differential connectivity are more highly connected 
in 20wk high-fat males than 30wk high-fat males or 20wk low-fat males, depending on 
comparison. 
Gene set enrichment analysis. Over-representation analysis (ORA) was performed using the 
WEB-based Gene Set Analysis Toolkit v2019355 on genes overexpressed in individual β-cell 
subtypes (Table 3.1), β-cell-specific genes (Table 3.3), and genes within blue and brown 
expression modules (Table 3.4), using all genes expressed in the sc-RNAseq data set as a 
reference set. Analysis included gene ontologies (biological process, cellular component, 







SM/J islets contain four β-cell subpopulations. We developed an analysis pipeline that integrates 
sc- and bulk RNA-seq data to characterize the transcriptional changes in β-cells from obese SM/J 
mice as they improve glycemic control with age (Figure 3.1A). We identified islet cells (α, β, 
and δ), exocrine cells (acinar and ductal), vascular cells (smooth muscle and endothelial), and 
immune cells (B cells and macrophages) (Figure 3.1B). Subsequent clustering of β-cells 
revealed 4 subpopulations, labeled Beta 1-4 (Figure 3.1C, Figure 3.8F). 20wk hyperglycemic 
high-fat males have a significantly larger Beta 1 population compared to 30wk normoglycemic 
high-fat males and 20wk low-fat males, at the expense of a diminished Beta 2 population 
(Figure 3.1 D-E). 
β-cell subpopulations have unique expression signatures. To identify genes that are 
overexpressed in each subpopulation, we performed differential expression analysis between 
each subpopulation and all other β-cells. The top ten highest differentially expressed genes 
within each subtype are visualized in Figure 3.2. Gene enrichment analysis on the overexpressed 
genes in each subpopulation reveals potential specialization: Beta 1 - insulin secretion, Beta 2 – 
hypoxia response, Beta 3 – cell polarity, Beta 4 – stress response (Table 3.1).  
SM/J β-cells uniquely express 316 genes. To identify genes primarily expressed by β-cells in 
scRNA-seq data, we employed a beta hurdle model, which allowed us to estimate the relative 
contribution of each cell type to total gene expression (Figure 3.9). To be considered a β-cell-
specific gene, we required β-cells to account for at least 80% of total expression within each 
cohort (Figure 3.3A). We identified 316 β-cell-specific genes (Table 3.2), comprised of genes 
canonically associated with β-cell identity, including Ucn3, Gcgr, and Slc2a2 (Figure 3.3B-E) 
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and genes with unknown function in β-cells (Figure 3.3F-G). Overrepresentation analysis 
revealed enrichment for terms associated with β-cell function, including mature onset diabetes of 
the young (MODY) and carbohydrate homeostasis, along with terms related to neuron function 
including neuroactive ligand-receptor interaction, neuron projection terminus, and axon part 
(Table 3.3). We then sought to discover if β-cell-specific genes were overexpressed within any 
of the β-cell subpopulations. We identified 20 β-cell-specific genes overexpressed in Beta 1 
cells, far more than would be expected by chance (Figure 3.3H). 
β-cell genes are differentially expressed by age, diet, and sex. To robustly characterize β-cell 
gene expression in SM/J mice, we normalized bulk RNA-seq data from 20- and 30-week high- 
and low-fat males and females (4 per cohort, n=32) using only the 316 β-cell-specific genes. 
Principal components analysis on the normalized expression data revealed high-fat males 
separated from other cohorts (Figure 3.4A). This is consistent with our previous studies showing 
that high-fat fed SM/J males show a more extreme glycemic response than other cohorts342,343. 
Pairwise comparison revealed 8 differentially expressed genes between 20- and 30wk high-fat 
males and 2 differentially expressed females between 20- and 30wk high-fat females (Figure 
3.4B). 20wk male mice differentially express 104 genes between diets, while 30wk male mice 
differentially expressed 17. Females differentially expressed a largely consistent set of genes 
between diets in 20- and 30wk cohorts. We focused subsequent analyses between 20wk and 
30wk high-fat males (Figure 3.4C), and 20wk high and low-fat males (Figure 3.4E). These 
analyses allow comparison between hyper- and normoglycemic-obese mice, and between 
hyperglycemic-obese and normoglycemic-lean mice. We highlight two genes with unknown 
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roles in β-cell function, Pdyn and Fam151a, as differentially expressed between 20- and 30wk 
high-fat males (Figure 3.4D), and 20wk high and low-fat males (Figure 3.4F), respectively.  
β-cell gene expression networks correlate with metabolic traits. We performed network analysis 
to characterize how groups of genes behaved across age and dietary cohorts. We performed 
weighted gene co-expression network analysis (WGCNA), which groups similarly co-expressed 
genes into discreet modules, then correlates these modules with phenotypes353. We collected 
metabolic phenotypes in the bulk RNA-seq mice including body weight, blood glucose level, 
serum insulin, and islet-specific phenotypes including glucose-stimulated insulin secretion, basal 
insulin secretion, and islet insulin content (Figure 3.10). Performing co-expression analysis 
identified 9 discreet modules of genes, 6 of which correlated significantly with at least one 
phenotype (Figure 3.11). We highlight the blue and brown modules for their correlation with 
phenotypes relevant to hyperglycemic obese 20wk high-fat mice. 
Blue module associated with fatty acid metabolism correlates with blood glucose level and is 
altered by age in obese mice. The blue module contains 42 genes, and over-representation 
analysis reveals enrichment for genes related to fatty acid metabolism (Table 3.4). Blue network 
eigengene expression correlates with blood glucose level across all mice (Figure 3.5A, Figure 
3.12F). This correlation is driven by the resolution of hyperglycemia in high-fat mice (Figure 
3.5A, Figure 3.12B). Strength of individual gene membership within the blue module correlates 
with strength of correlation to blood glucose levels (Figure 3.5B). The blue network is 
visualized as the sum of gene-pair correlations (Figure 3.12D). This network was then subset 
into 20wk high-fat males (Figure 3.5D) and 30wk high-fat males (Figure 3.5E). Four genes 
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were identified as differentially connected between networks, although none were individually 
differentially expressed between 20- and 30wk high-fat males (Figure 3.5C). 
Brown module associated with β-cell function correlates with insulin levels and is influenced by 
diet. The brown module contains 39 genes, and over-representation analysis reveals enrichment 
for genes related to abnormal β-cell physiology (Table 3.4). Brown network eigengene 
expression negatively correlates with serum insulin levels across all mice (Figure 3.6A, Figure 
3.12E). This correlation is driven in part by diet, where high-fat mice have high levels of 
circulating insulin (Figure 3.6A, Figure 3.12A). Strength of gene membership in the brown 
module negatively correlates with strength of correlation to serum insulin level, including 
Fam151a, which is highly connected in the brown network (Figure 3.6B). Further, expression of 
Fam151a negatively correlates with serum insulin levels across all cohorts, independent of 
network construction (Figure 3.6C). The brown network is visualized as the sum of gene-pair 
correlations (Figure 3.12C). The network was subset into 20wk high-fat males (Figure 3.6D) 
and 20wk low-fat males (Figure 3.5E), revealing strong network structure in 20wk low-fat 
males. Differential connectivity was calculated between 20wk high and low-fat males to identify 
genetic network connectivity that was altered between cohorts (Figure 3.6F). Differential 
connectivity was contrasted with differential expression between 20wk high and low-fat males, 
revealing Fam151a to be both differentially connected and differentially expressed (Figure 
3.6G).  
Single cell expression of Pdyn and Fam151a are influenced by age and diet. We sought to 
determine if the differential expression of Pdyn and Fam151a seen in the bulk analysis is 
recapitulated at the single cell level. We compared expression of Pdyn in all β-cells between 
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20wk high-fat males and 30wk high-fat males (Figure 3.7A) and found significant differential 
expression, driven by differences in the proportion of β-cells expressing Pdyn (Figure 3.7B). 
Likewise, Fam151a is differentially expressed across all β-cells between 20wk high-fat males 
and 20wk low-fat males (Figure 3.7C), driven by differences in the proportion of β-cells 
expressing Fam151a (Figure 3.7D). To determine if differential expression could be attributed 
to changes in β-cell subpopulation proportions, we calculated differential expression between the 
two most prominent subtypes, Beta 1 and Beta 2, revealing significant differential expression of 
Pdyn and Fam151a (Figure 3.7E). While Pdyn is overexpressed in Beta 2 cells, which are 
prominent in 30wk high-fat males, Fam151a is overexpressed in Beta 1 cells, which are 
prominent in 20wk high-fat males. This suggests differential expression of Pdyn can be 
attributed to differences in subpopulation proportions, but not for differential expression of 
Fam151a. Assessing differential expression in Beta 1 cells between 20wk high-fat males and 
20wk low-fat males revealed Fam151a was very significantly differently expressed (Figure 
3.7F), driven by an increase in the proportion of β-cells expressing Fam151a (Figure 3.7G), 
which could contribute to the differential expression of Fam151a between 20wk high-fat males 
and 20wk low-fat males seen in the bulk data. 
3.5 Discussion 
Pancreatic β-cell heterogeneity has been studied extensively using single cell technology 
because of the cell type’s unique insulin-secreting capabilities and central role in diabetes 
etiology. Several groups have proposed the existence of functionally distinct β-cell 
subpopulations24,25,45,356, but their existence and relevance to insulin homeostasis remain 
controversial. We identified 4 β-cell populations (Figure 3.1-3.2, Figure 3.8), Beta 1-4, across 
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hyperglycemic-obese, normoglycemic-obese, and normoglycemic-lean mice. While the 
functional roles assigned to each population are based on gene enrichment analysis and open to 
interpretation (Table 3.1), the relative proportion of each population changes in conjunction with 
islet function across cohorts, suggesting a functional relevance to overall β-cell population 
structure. 
Beta 1 cells are most prevalent in hyperglycemic obese mice and are associated with 
elevated basal insulin secretion and low insulin content. Beta 1 cells overexpress mature markers 
including Ucn3357, Pdx1246, and Acly358, and negative regulators of glucose-stimulated insulin 
secretion including Abcc8359, G6pc2360, and Ucp2361. Terms associated with Beta 1 cells include 
signal release and hormone transport. Beta 1 cells appear to be primed for insulin release, but not 
to perform glucose-stimulated insulin secretion. Farack et al356 identified a subpopulation of 
“extreme” β-cells that specialize in basal insulin secretion, with high insulin expression and low 
mature insulin content. These cells have high expression of markers Ucn3, Acly, and Pdx1, and 
increase in proportion in obese mice. The Beta 1 cells we identified are similar to “extreme” β-
cells based on their mature profile, potentially limited glucose response, and abundance in  
diabetic obese mice. Validation is required to determine if these β-cells function by over-
expressing insulin secretion pathway components while suppressing glucose response 
mechanisms. 
Beta 2 cells are prevalent in normoglycemic-obese and normoglycemic-lean mice and are 
associated with high GSIS and high islet insulin content. Beta 2 cells are enriched for response to 
oxygen levels, pyruvate metabolism, and nucleotide phosphorylation, each associated with 
protection from hypoxia362,363. These cells are equally prevalent in obese 30wk high-fat males 
69 
 
and lean 20wk low-fat males, which differ greatly in islet mass, suggesting Beta 2 cells are not a 
hypoxic population. Further, 20wk high-fat males have similar islet mass to 30wk high-fat males, 
but a much smaller Beta 2 population. Importantly, 30wk high-fat males have healthier glycemic 
parameters than 20wk high-fat males342,343. Several groups have identified a subset of heavily 
vascularized islets that have elevated oxygen consumption and superior GSIS at the cost of 
susceptibility to hypoxia. We suspect Beta 2 cells represent a highly functional β-cell population 
that confer protection against hypoxia154,156. Given their abundance in functional islets from both 
obese and lean normoglycemic mice, we hypothesize Beta 2 cells represent a mature, and 
possibly stress-resistant β-cell population. 
Beta 3 cells are prevalent in normoglycemic obese mice which have elevated β-cell mass, 
high GSIS, and high insulin content. Beta 3 cells overexpress plasma membrane components, 
including several claudin family members, and ribosome components. Claudins provide 
structural integrity to tight junctions, which maintain cell polarity364. Polarity in β-cells serves as 
both a driver and a characteristic of mature, highly functional β-cells43,45,365. Cldn4, Cldn3, and 
Cldn7 are all upregulated in Beta 3 cells and associated with mature β-cell function366. Beta 3 
cells upregulate 7 ribosome genes and elevated ribosome biogenesis is associated with increased 
β-cell apoptosis367, β-cell replication45, and mature β-cell function368, making the functional 
relevance of overexpression unclear. One gene, Rpl7, is associated with mature β-cell 
function369, while Rpl23 protects against apoptosis370. From this we conclude that Beta 3 cells 
represent a polarized and mature β-cell population. 
Beta 4 cells are the lowest in abundance and elevated in lean males compared to obese 
males. Terms associated with Beta 4 cells include response to stress and response to 
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topologically incorrect protein. In addition to overexpression of UPR components, Beta 4 cells 
have significant down regulation of Ins1 and Ucn3. Several groups have identified β-cell 
subpopulations based on a stress response signature91,92,371, which have coalesced into a theory 
about stress response cycling, where β-cells go through periods of UPR activation and low 
insulin production to clear misfolded proteins21,259. Interestingly, 20wk low-fat mice have a 
similar proportion of stress response cycling cells compared to other groups (~7%), however this 
population is significantly smaller in high-fat males, suggesting that stress response cycling may 
be suppressed by obesity. 
Efforts to describe β-cell transcriptional heterogeneity are marred by lack of consensus 
across scRNA-seq studies372. This is attributed to low read depth, which results in differences in 
gene capture driven by technical artifacts and random chance rather than biological variation102. 
Further, it is unclear what level of gene expression fold change is meaningful between individual 
cells, rendering single cell data poorly suited to assess differential expression across different 
cohorts. To address these problems, we developed a technique to integrate single cell data with 
bulk RNA-seq data (Figure 3.3, Figure 3.9), which is not inhibited by these technical 
limitations, to assess β-cell-specific differential expression across cohorts of high- and low-fat 
fed male and female SM/J mice. While the list of genes identified as β-cell-specific is only 316 
genes (Table 3.2), we are highly confident of their specificity to β-cells, allowing for robust 
assessment of differential expression and network analysis. Sub-setting the bulk RNA-seq data 
by β-cell-specific genes provided a small but highly-focused search space to identify genes that 
influence β-cell function in hyperglycemic-obesity, normoglycemic-obesity, and healthy mice. 
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We identified Pdyn as a novel candidate gene associated with improved glycemic control 
in males. Pdyn encodes Proenkephalin-b, which is cleaved into dynorphin A and dynorphin B, 
and exert effects through the κ-opioid receptor373. While Pdyn’s role in β-cell function is 
unknown, activation of the κ-opioid receptor reduces hyperglycemia in diabetic mice and  β-cells 
secrete dynorphin A in a glucose-dependent manner374,375. Further, Pdyn expression is associated 
with regulation by Pax6 and Lkb1, hallmarks of mature β-cells376,377. Pdyn is over expressed in 
Beta 2 cells, which are increased in normoglycemic-obese mice, and may link improved β-cell 
function with hypoxia response, as Pdyn provides protection from hypoxia in lung and neuronal 
tissue378,379. 
We used weighted gene co-expression network analysis (WGCNA) to identify networks 
of co-expressed β-cell genes and to assess how networks correlate with metabolic and islet 
phenotypes (Figure 3.10). Previous efforts to construct networks in islet RNA-seq data failed to 
account for cell-type specific gene expression, making it difficult to determine if these networks 
operate within an individual cell380–382. Our analysis revealed 6 β-cell-specific modules that 
correlate with phenotypes, two of which were enriched for intriguing ontology terms (Figure 
3.11). We chose to explore these networks in depth to assess the context in which they were 
relevant to β-cell function in obesity. 
The blue module is highly expressed in 20wk high-fat males, strongly correlating with 
blood glucose concentration (Figure 3.5, Figure 3.12). The blue module is enriched with fatty 
acid metabolism genes, which are heavily implicated in obesity and diabetes (Table 3.4). In β-
cells, fatty acid metabolism provides a glucose-independent stimulus for insulin release383,384. 
While short term fatty acid exposure enhances GSIS, prolonged exposure decreases GSIS and 
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reduces insulin content383,385. Fatty acid metabolism protects against glucotoxicity-induced 
damage, allowing cells to convert excess glucose into glycerol, which bypasses ROS 
generation386. How this network connects to the β-cell dysfunction seen in obese, hyperglycemic 
20wk high-fat mice is not immediately clear. Since fatty acid metabolism can stimulate insulin 
release, it is possible that prolonged activation of this network promotes elevated basal insulin 
secretion but inhibits GSIS. Expression of this network may be related to the abundance of Beta 
1 cells in 20k high-fat males, which are geared toward basal insulin release. One gene in the blue 
module, Entpd3, confers susceptibility to diet-induced obesity and hyperglycemia387. This fatty 
acid metabolism gene network may provide a link between the increased proportion of Beta 1 
cells and the β-cell dysfunction observed in 20wk high-fat males. 
The brown module is highly expressed in lean mice and negatively correlates with serum 
insulin levels (Figure 3.6, Figure 3.12). Unsurprisingly, this module is enriched for genes 
associated with β-cell physiology (Table 3.4). We focused on how the network behaved in 20wk 
high and low-fat males, as they provided strong contrast for serum insulin levels and β-cell 
function. Core members of this network include known markers of β-cell maturation including 
Ucn3, Slc2a2, and Pcsk1. This network is suppressed in 20wk high-fat males, who have 
dysfunctional β-cells. We homed in on Fam151a, a gene highly connected within the network, 
that independently correlates with serum insulin levels. Fam151a is both differentially expressed 
and differentially connected within the brown module between 20wk high-fat and 20wk low-fat 
mice, suggesting an important role within the network and a potential link between serum insulin 
levels and β-cell function. Fam151a is a membrane embedded protein of unknown function, but 
it has been associated with dysregulated insulin secretion in Isl1 knockout mice, and falls within 
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a QTL associated with diabetes388–390. Further work will explore how Fam151a influences β-cell 
function in the context of obesity. 
We explored if subpopulation composition contributes to differential expression of Pdyn 
and Fam151a (Figure 3.7). Total Pdyn expression increased across all β-cells between 20 and 
30wk high-fat fed males, in agreement with the bulk RNA-seq data. Pdyn is overexpressed in 
Beta 2 cells, which increase in proportion between 20 and 30 weeks in high-fat mice, suggesting 
differential expression of Pdyn is driven by a change in subpopulation proportions. Investigation 
into how Pdyn influences in β-cell function must consider that knockout/overexpression may 
affect subpopulations differently, and that subpopulation structure changes based on metabolic 
context. Likewise, total Fam151a increased across all β-cells between 20wk high and low-fat 
males, in agreement with the bulk RNA-seq data. However, Fam151a is strongly overexpressed 
in Beta 1 cells, which are most abundant in 20wk high-fat males. To explore this discrepancy, we 
performed differential expression analysis in Beta 1 cells between 20wk high and 20wk low-fat 
males and found Fam151a expression is significantly higher in 20wk low-fat male Beta 1 cells. 
Thus, while the proportion of Beta 1 cells is lower in 20wk low-fat mice, the expression of 
Fam151a is significantly increased in their Beta 1 cells. These findings underscore the 
complexity of gene expression and suggest it is important to consider both subpopulation 
composition and expression within subpopulations when exploring β-cell heterogeneity in 
diabetes and obesity. 
In summary, we identified 4 β-cell subpopulations whose relative proportions change 
depending on metabolic state. Beta 1 cells are primed for basal insulin secretion and 
proportionally high in hyperglycemic obese mice. Beta 2 cells are primed for protection from 
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hypoxia associated with enhanced function and are abundant in normoglycemic obese and 
normoglycemic lean mice at the expense of Beta 1 cells. In conjunction, hyperglycemic obese 
mice express a highly connected genetic network associated with fatty acid metabolism, which is 
lost as glycemic control improves. The interplay between changing β-cell subpopulations and 
decreased fatty acid metabolism likely contributes to the improved β-cell function and 
subsequent restoration of glycemic control seen in obese SM/J mice342,343. This study provides a 
road map for exploring cellular heterogeneity by integrating sc- and bulk RNA-seq data, 
allowing for robust characterization of subpopulation structure, differential expression, and 
















3.6 Figures and Legends 
 
Figure 3.1. SM/J islets contain four subpopulations of β-cells. (A) Data analysis pipeline 
identifies subpopulations of β-cells and integrates bulk and single cell RNA sequencing data. (B) 
Single cell RNA sequencing UMAP plot of islet tissue. VSMC – vascular smooth muscle cell, 
VEC – vascular endothelial cell. (C) Single cell RNA sequencing UMAP of 4 subpopulations of 
β-cells. (D) Bootstrap analysis quantifies relative proportions of β-cell subpopulations across 
cohorts. Black dot represents estimated proportion, colored bars illustrate 95% confidence 
interval. Cell type composition estimates with non-overlapping confidence intervals are 
significantly different. (E) Ternary plot illustrates differences in subtype composition of Beta 1-3 
in high-fat SM/J mice. HF20 – 20wk high-fat female, HF30 – 30wk high-fat female, HM20 – 





Figure 3.2. β-cell subpopulations have unique gene expression signatures. (A) Heat map for top 
10 differentially expressed genes in each β-cell subpopulation. Yellow is highly expressed; 












Figure 3.3. Single cell RNA sequencing identifies β-cell-specific genes. (A)  Total gene 
expression and β-cell-specific contribution to gene expression in 20wk low-fat female β-cells. 
Gold line indicates threshold for β-cell-specific expression. Red dots identify genes that pass the 
threshold cutoff in this cohort. Arrows identify highly expressed genes associated with β-cell 
identity. Genes must pass threshold in all cohorts to be considered β-cell-specific in the rest of 
the analysis. (B) UMAP plot of all islet cell types. UMAP plots for β-cell-specific expression of 
known β-cell markers (C) Ucn3, (D) Gcgr, (E) Slc2a2. UMAP plots for β-cell-specific 
expression of novel β-cell markers (F) Pdyn, and (G) Fam151a. (H) Permutation analysis of β-
cell-specific genes in Beta 1 overexpressed genes. Distribution shows expected number of β-cell-
specific genes in Beta 1 overexpressed gene set based on chance (n = 1000 permutations), red 
line indicates number of β-cell-specific genes in Beta 1 overexpressed gene set. P-value indicates 




Figure 3.4. β-cell-specific genes are differentially expressed by age, diet, and sex. (A) Principal 
component analysis of bulk RNA sequencing data normalized with only β-cell-specific genes. 
(B) Number of differentially expressed genes in females and males, across diets and age. (C) 
Differentially expressed genes between 20wk high-fat males and 30wk high-fat males. (D) Pdyn 
is differentially expressed in high-fat males. (E) Differentially expressed genes between 20wk 
high-fat males and 20wk low-fat males. (F) Fam151a is differentially expressed in 20wk males. 
Blue genes are significantly under-expressed in comparison, red genes are significantly over-
expressed. Vertical golden lines indicate threshold for significance based on average log fold 
change, horizontal line indicates threshold for significance based on FDR corrected p-value. **p-
value <0.01, **** p-value < 0.0001 in FDR corrected pairwise comparison. HF20 – 20wk high-
fat female, HF30 – 30wk high-fat female, HM20 – 20wk high-fat male, HM30 – 30wk high-fat 




Figure 3.5. Blue modules network structure is altered by age in high-fat male mice. (A) Blue 
module heatmap, eigengene expression, and blood glucose levels across all individuals. (B)  
Correlation between strength of module membership and blood glucose levels for blue module. 
(C) Total and differential connectivity between blue module genes in 20wk and 30wk high-fat 
male mice. Vertical golden lines indicate threshold for differential connectivity. (D) Blue module 
network structure in 20wk high-fat males and (E) 30wk high-fat males. Size and color of node 
indicates overall connectivity within the network, thickness of edges indicates strength of 




Figure 3.6. Brown module network structure is altered by diet in 20wk male mice. (A) Brown 
module heatmap, eigengene expression, and insulin levels across all individuals. (B)  Correlation 
between strength of module membership and serum insulin levels for brown module. Gene of 
interest, Fam151a, is highlighted. (C) Expression of Fam151a correlates with serum insulin 
levels across all individuals independent of module membership. Light red – 20wk high-fat mice, 
dark red – 30wk high-fat mice, light blue – 20wk low-fat mice, dark blue – 30wk low-fat fed 
mice. (D) Brown module network in 20wk high-fat males and (E) 20wk low-fat males. Gene of 
interest, Fam151a, is highlighted in yellow. Size and color of node indicates connectivity within 
the network, edge thickness indicates strength of correlation between gene pairs. (F) Total and 
differential connectivity between brown module genes in high and low-fat male SM/J mice. 
Vertical golden lines indicate threshold for significant differential connectivity. Gene of interest, 
Fam151a, is highlighted. (G) Differential connectivity and differential expression of brown 
module genes between 20wk high and 20wk low-fat males. Vertical golden lines indicate 
threshold for differential connectivity, Horizontal golden line indicates threshold for differential 




Figure 3.7. Pdyn and Fam151a are differentially expressed in β-cell subtypes. (A) Expression of 
β-cell-specific genes across all β-cells between 20wk and 30wk high-fat males. (B) Percent of β-
cells in 20wk and 30wk high-fat males expressing β-cell-specific genes. (C)  Expression of β-
cell-specific genes across all β-cells between 20wk high and low-fat males. (D) Percent of β-cells 
in 20wk high and low-fat males expressing β-cell-specific genes. (E) Comparison of Pdyn and 
Fam151a expression across β-cell subtypes. (F) Expression of β-cell-specific genes in beta 1 
cells between 20wk high-fat and 20wk low-fat fed mice. (G) Precent of beta 1 cells expressing 
beta specific genes between 20wk high-fat and 20wk low-fat fed mice. Blue genes are 
significantly under-expressed in comparison, red genes are significantly over-expressed. Vertical 
golden lines indicate threshold for significance based on average log fold change, horizontal line 





Figure 3.8. Single cell RNA sequencing quality control. (A) Total counts, features, and 
mitochondrial RNA expression plotted for each cell. Cells within blue box and without 
mitochondrial gene expression were included in analysis. (B) Number of cells identified in 
individual mice prior to quality control, (C) and after quality control. (D) Expression of Ins2 
across all cells prior to ambient RNA removing using SoupX, (E) and after ambient RNA 
removal. (F) Resolution analysis to determine the number of β-cell subpopulations. Selected 




Figure 3.9. Quantifying expected expression for β-cell expression of Dcd. (A) Distribution of 
expression across all β-cells. (B)  Cullen and Frey analysis identifies Dcd expression to be beta 
distributed. (C) Kolmogorov-Smirnov test identifies alpha and beta parameters that minimize Ks 
between real (blue line) and simulated (red line) distribution of cells expressing Dcd. (D) 
Estimating percent of cells not expressing Dcd due to gene drop out by iterating alpha and beta 
parameters that minimize Ks  between real and simulated data. (E) Density plot visualizing 
estimated parameters for distribution of Dcd expression. Red line shows distribution of actual 
data, black line shows distribution of simulated data based on optimal alpha and beta parameters. 





Figure 3.10. Metabolic and islet phenotypes from bulk RNA sequencing mice. (A) body weight, 
(B) blood glucose, (C) serum insulin levels collected after 4-hour fast. (D) Glucose-stimulated 
insulin secretion (GSIS), (E) Basal insulin secretion, (F) Islet insulin content collected after 
isolated islets were rested overnight. N = 4 mice per age X sex X diet cohort. N= 10 islets per 
individual for islet phenotypes. Middle bar represents mean, box represents 25th and 75th quartile, 












Figure 3.11. Correlation between phenotype and module eigengene expression. Number of 
genes within each module reported on y-axis, phenotypic trait reported on x-axis. For each 
module-trait relationship, the Pearson correlation between eigengene expression and phenotype 
value is reported (top) along with an FDR-corrected p-value for the correlation (bottom). Color 







Figure 3.12. Overview of brown and blue modules. (A) Principal component analysis of gene 
expression within the brown module across all cohorts, segregated by diet. (B) Principal 
component analysis of gene expression within the blue module, segregated by cohort. (C) Brown 
module network structure in across all cohorts. Gene of interest, Fam151a, is highlighted in 
yellow. Size and color of node indicates overall connectivity within the network, thickness of 
edges indicates strength of correlation between gene pairs. (D) Blue module network structure in 
across all cohorts. Size and color of node indicates overall connectivity within the network, 
thickness of edges indicates strength of correlation between gene pairs. (E)  Correlation between 
brown module eigengene expression and serum insulin levels across all cohorts. (F) Correlation 




Table 3.1. Top five results for over-representation analysis (ORA) on significantly enriched 
genes within each β-cell subpopulation, including gene ontology terms. 
Gene Set Description Ratio FDR
GO:0023061 signal release 4.60 6.89E-13
GO:0009914 hormone transport 4.72 3.23E-09
GO:0030133 transport vesicle 3.90 3.45E-07
GO:0019932 second-messenger-mediated signaling 4.34 3.45E-07
GO:0033500 carbohydrate homeostasis 3.89 0.000044254
GO:0070482 response to oxygen levels 5.49 7.22E-08
GO:0006090 pyruvate metabolic process 10.55 6.13E-07
GO:0046939 nucleotide phosphorylation 10.45 2.3329E-06
GO:0009132 nucleoside diphosphate metabolic process 8.84 2.5493E-06
GO:0006091 generation of precursor metabolites and energy 4.53 3.3401E-06
GO:0016327 apicolateral plasma membrane 31.35 0.0042583
GO:0003735 structural constituent of ribosome 7.90 0.0042583
GO:0005840 ribosome 5.42 0.02957
GO:0044445 cytosolic part 5.42 0.02957
GO:0031012 extracellular matrix 4.66 0.02957
GO:0043620 regulation of DNA-templated transcription in response to stress 37.35 0.00021552
GO:0045926 negative regulation of growth 12.11 0.0044405
GO:0035966 response to topologically incorrect protein 16.41 0.0044405
GO:0042594 response to starvation 11.63 0.017622
















Table 3.2. β-cell-specific genes identified in single cell RNA sequencing analysis. 
0610009E02Rik Bace2 Dapl1 Gcgr Il17re Mrgpre Qpct Tenm3
1700084C01Rik Barhl1 Defb1 Gdf11 Impg2 Mrm1 Rasgrf1 Th
1810019D21Rik BC017158 Dennd6b Gdpgp1 Inpp5j Mt3 Rbm20 Thrsp
1810059H22Rik BC051226 Dgke Ggt7 Ins1 Mtmr10 Rec8 Tmem121
2210404J11Rik Bdh1 Dgkg Gipr Ins2 Mtss1l Rhbdl2 Tmem150c
2900005J15Rik Brsk1 Diras2 Gjd2 Insrr Naaa Rhd Tmem180
A330050F15Rik Brsk2 Dis3l Glb1l2 Intu Nars2 Rims3 Tmem215
A830039N20Rik C030014I23Rik Dmpk Glt1d1 Isoc2b Nckap5 Rit2 Tmem231
A930011G23Rik C1rl Dner Glt28d2 Jag2 Ndrg4 Rnf182 Trmt61b
Abcb4 C2cd4a Dnmt3b Gm10075 Jph4 Nkx6-1 Rnls Trpm5
Abcb6 C2cd4c Dolpp1 Gm10567 Kcnb2 Nrcam RP24-510G5.4 Ttc26
Abhd15 C330027C09Rik Dusp23 Gm10941 Kcnh1 Nrip3 Rps6kc1 Tti2
AC102739.1 Car10 E130317F20Rik Gm11789 Kcnh6 Nupl1 Rpusd1 Ttyh1
AC130216.1 Cartpt E530001K10Rik Gm1631 Kcnip1 Nyap2 Rtkn2 Tubb3
AC131780.1 Casr Efna5 Gm17538 Kctd15 Osbpl7 Rtn4ip1 Ucn3
Acot11 Ccbl1 Eme2 Gm5105 Kdm1b Otub2 S100a9 Ufsp1
Acpl2 Ccdc149 Enthd2 Gm5860 Kif19a Ovol2 Sap130 Ush2a
Acsl6 Ccdc162 Entpd3 Gp1bb Klhl8 P2ry1 Scel Utp14b
Acss2 Ccl28 Erc2 Gpr158 Kpna2 Pan2 Sec16b Vgf
Adh1 Cdh4 Esrrg Gramd1c Ky Papss2 Sgcz Vps37c
Adora1 Cdh8 Exog Grem2 Lgi1 Pcsk1 Shisa2 Vstm2l
Adra2a Cecr5 Fam151a Grin1 Lhx1 Pcsk4 Six4 Wdr25
Akr1c14 Cep135 Fam160a1 Grip1 Lphn3 Pde4a Slc16a9 Whrn
Akr1e1 Cep76 Fam179a Gstm4 Lrrc16b Pde5a Slc25a35 Xpo5
Aldh1l2 Cep85 Fam217b Gtf2e1 Lrrtm2 Pdyn Slc25a40 Xrcc3
Amigo3 Cep97 Fbxo16 Gucy2c Mapt Pemt Slc2a13 Zbtb48
Amph Cmbl Ffar3 Hapln4 Mccc2 Pgap3 Slc2a2 Zc3h3
Angel1 Cnnm1 Fhdc1 Helq Mcph1 Pitpnm3 Slc35d3 Zdhhc24
Angptl7 Cntfr Fig4 Hhat Meig1 Plch1 Slc4a10 Zfp174
Ankrd27 Cntn1 Flrt1 Hist1h1d Mettl7a1 Pnpla3 Slc5a6 Zfp324
Ankrd49 Cox6a2 Fmo1 Hist1h4i Mfsd6l Poc5 Slc9a9 Zfp346
Ap3m2 Cpne4 Fras1 Hist2h2bb Mfsd8 Poll Slco1a6 Zfp518b
Ap4b1 Crocc Frmd5 Hist2h3c2 Mlxipl Pou6f1 Smoc1 Zfp692
Apba1 Csn3 Fut1 Hist2h4 Mmp24 Ppm1e Snx25 Zfp758
Aqp4 Cst6 Fut4 Hlcs Mns1 Ppp1r1a Srrm4 Zfp839
Ascl1 Cyb561d1 G6pc2 Hmgcll1 Mnx1 Ppp1r42 St8sia1 Zscan22
Asic1 Cyp7b1 Gabbr2 Hps5 Mon1b Prlr St8sia5
Atg4c D3Bwg0562e Gad1 Hs3st6 Morn4 Prrt1 Tat
B230216N24Rik D630045J12Rik Galnt14 Hspa12a Mpp3 Prss53 Tcaim





Table 3.3. Top five results for over-representation analysis (ORA) for β-cell-specific genes, 
including gene ontology and mammalian phenotype ontology terms. 
Gene Set Description Ratio FDR
mmu04950 Maturity onset diabetes of the young 8.38 0.0808
mmu04080 Neuroactive ligand-receptor interaction 5.05 0.0808
GO:0044306 neuron projection terminus 3.97 0.0808
GO:0033500 carbohydrate homeostasis 3.19 0.0808
GO:0033267 axon part 2.48 0.0808  
 
 
Table 3.4. Type five results for over-representation analysis (ORA) on genes within brown and 
blue modules, including gene ontology and KEGG pathway terms. 
Gene Set Description Ratio FDR
MP:0003562 abnormal pancreatic beta cell physiology 12.34 0.1381
MP:0010147 abnormal endocrine pancreas physiology 11.99 0.1381
MP:0003059 decreased insulin secretion 15.64 0.2031
MP:0004994 abnormal brain wave pattern 24.60 0.2942
MP:0002693 abnormal pancreas physiology 8.36 0.2942
mmu00072 Synthesis and degradation of ketone bodies 72.44 0.0964
mmu00601 Glycosphingolipid biosynthesis 39.01 0.1765
mmu00650 Butanoate metabolism 31.69 0.1798
mmu04976 Bile secretion 14.91 0.6046





































Pancreatic β-cells are optimized to secrete insulin, a process critical for maintaining 
appropriate blood glucose concentration. In type 2 diabetes, peripheral insulin resistance 
promotes initial β-cell expansion, but ultimately results in β-cell death and dysfunction2–4. 
Obesity raises the risk of developing type 2 diabetes 27-76 fold, while approximately 60% of 
individuals with diabetes are obese268–271. Despite the stress obesity places on β-cells, 10-30% of 
obese individuals maintain glycemic control and are at low risk for developing diabetes276. These 
low-risk obese individuals have elevated β-cell mass and improved insulin secretion compared to 
BMI-matched diabetic-obese individuals2,13,277,278. Understanding the differences in β-cell 
physiology between these populations may reveal therapeutic strategies for maintaining and 
improving glycemic control in obese individuals. 
Like in humans, diabetic risk in obese mice depends on genetic background281–284. Variation 
in β-cell heterogeneity likely underlies variability in islet stress response, and thus needs to be 
accounted for when comparing nondiabetic-obese and diabetic-obese populations. No current 
mouse model is well-suited to examine physiological differences in β-cell health between 
nondiabetic-obese and diabetic-obese states. Cell sorting, imaging, and sequencing technologies 
have allowed for analysis of multiple β-cell properties, revealing that β-cells vary in morphology, 
function, and gene expression. The importance of heterogeneity is reinforced by observations 
that β-cells are subject to variable fates in diabetes including apoptosis, replication, and 
dedifferentiation2,26–28. Characterization of β-cell heterogeneity has led to questions about its role 
in diabetic etiology and therapy29. Examining heterogeneity lends itself to questions about the 
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applications and limitations of β-cell plasticity, which can focus research aimed at improving β-
cell function. 
The SM/J inbred mouse strain has been used to study interactions between diet and 
metabolism, and more recently has uncovered genetic architecture underlying diet-induced 
obesity and glucose homeostasis290–295. After 20 weeks on a high fat diet, SM/J mice display 
characteristics of diabetic-obese mice, including elevated adiposity, hyperglycemia, and glucose 
intolerance296. We have previously shown that by 30 weeks of age, high fat-fed SM/J mice enter 
diabetic remission, characterized by normalized fasting blood glucose, and greatly improved 
glucose tolerance and insulin sensitivity297. Given the central role of β-cell health in 
susceptibility to diabetic-obesity, we hypothesize that obese SM/J mice undergo restoration of 
functional β-cell mass during the resolution of hyperglycemia. By contrasting β-cells in 
hyperglycemic-obese and normoglycemic-obese. Given the increasing relevance of β-cell 
heterogeneity in diabetes research, we also sought to characterize β-cell subpopulations in obese 
SM/J mice, and how they contribute to the hyper- and normoglycemic-obese states. By 
integrating phenotypic information with subpopulation structure, a more complete picture of β-
cell function in obese SM/J mice can be achieved.  
In chapter 2, we determined that increased insulin production and insulin sensitivity 
accompany improved glycemic control, driven by expanded β-cell mass and improved glucose-
stimulated insulin secretion.  To our knowledge, this is the first report of improved β-cell  
function in an obese inbred strain. β-cell hyperplasia is the primary driver of islet expansion in 
mouse models of obesity287,288. Some nondiabetic obese mice experience increased β-cell 
number, but do not show evidence for elevated β-cell replication in immunostaining of 
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pancreatic sections282,315. This has been attributed to technical artifacts in sampling could result 
in inflated variances which mask biological differences. This could be the case here, given that 
high fat-fed SM/J’s β-cell number is far above low fat-fed controls, that their β-cell number 
expands 2-fold during the resolution of hyperglycemia, yet we find no evidence for increased β-
cell replication. 20-week high fat-fed SM/J mice have an insulin secretion profile similar to 
diabetic-obese mice and humans, including blunted glucose-stimulate insulin release, elevated 
basal insulin secretion, and low islet insulin content, which resolves by 30 weeks.  
Three components of β-cell stress response may shed light on the perplexing 
improvement in glycemic control seen in SM/J mice: β-cell dedifferentiation, nascent β-cell 
maturation, and changes in β-cell subtype proportions. While early studies concluded 
overworked β-cells undergo apoptosis2,325–327, recent studies have suggested β-cells 
dedifferentiate into a dysfunctional, progenitor-like state, potentially as a defense mechanisms 
against prolonged glycemic stress236,279,328,329. These dedifferentiated β-cells have low insulin 
content and poor glucose-stimulated insulin secretion. Further, the dedifferentiated state is 
reversible in cultured conditions, revealing potential for therapeutic intervention239. It is feasible 
that obese SM/J mice have β-cells in the dedifferentiated state at 20-weeks, which would explain 
the low insulin content and poor functionality despite the elevated β-cell mass. Improvement in 
insulin sensitivity could ease glycemic stress, allowing dedifferentiated β-cells to redifferentiate 
by 30 weeks, reestablishing insulin production and secretion.   
Recent advances in single cell technology allows for identification of β-cell subtypes, 
based on functional characteristics and gene expression. Integrating sc-RNAseq with bulk 
RNAseq data leverages bulk sequencing’s high read depth, allowing for capture of lowly 
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expressed genes and robust expression analysis. Several tools can integrate sc- and bulk RNA-
seq data, focusing on deconvoluting bulk RNAseq data from heterogeneous tissue to account for 
differences in tissue composition90,340,341. These methods estimate and control for cell type 
abundance but do not identify cell type-specific expression signatures in bulk datasets. 
Analytical strategies that identify cellular gene expression signatures in bulk RNAseq data allow 
for robust cell type-specific differential expression analysis and complex network analysis that is 
currently not feasible in scRNA-seq data. 
In chapter 3 we characterized gene expression in β-cells from obese SM/J mice, who 
spontaneously transition from hyperglycemic to normoglycemic with improved β-cell function 
between 20 and 30 weeks of age342,343. Several groups have proposed the existence of 
functionally distinct β-cell subpopulations24,25,45,356, but their existence and relevance to insulin 
homeostasis remain controversial. We identified 4 β-cell populations, Beta 1-4, across 
hyperglycemic-obese, normoglycemic-obese, and normoglycemic-lean mice. While the 
functional roles assigned to each population are based on gene enrichment analysis and open to 
interpretation, the relative proportion of each population changes in conjunction with islet 
function across cohorts, suggesting a functional relevance to overall β-cell population structure. 
Beta 1 cells appear to be primed for insulin release, but not to perform glucose-stimulated 
insulin secretion. Farack et al356 identified a subpopulation of “extreme” β-cells that specialize in 
basal insulin secretion, with high insulin expression and low mature insulin content. The Beta 1 
cells we identified are similar to “extreme” β-cells based on their mature profile, potentially 
limited glucose response, and abundance in  diabetic obese mice. Beta 2 cells are enriched for 
response to oxygen levels, pyruvate metabolism, and nucleotide phosphorylation, each 
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associated with protection from hypoxia362,363. Several groups have identified a subset of heavily 
vascularized islets that have elevated oxygen consumption and superior GSIS at the cost of 
susceptibility to hypoxia. We suspect Beta 2 cells represent a highly functional β-cell population 
that confer protection against hypoxia154,156.Beta 3 cells overexpress plasma membrane 
components, including several claudin family members, and ribosome components. Polarity in β-
cells serves as both a driver and a characteristic of mature, highly functional β-cells43,45,365. 
Cldn4, Cldn3, and Cldn7 are all upregulated in Beta 3 cells and associated with mature β-cell 
function366. From this we conclude that Beta 3 cells represent a polarized and mature β-cell 
population. Terms associated with Beta 4 cells include response to stress and response to 
topologically incorrect protein. Several groups have identified β-cell subpopulations based on a 
stress response signature91,92,371, which have coalesced into a theory about stress response 
cycling, where β-cells go through periods of UPR activation and low insulin production to clear 
misfolded proteins21,259. Interestingly, 20wk low-fat mice have a similar proportion of stress 
response cycling cells compared to other groups (~7%), however this population is significantly 
smaller in high-fat males, suggesting that stress response cycling may be suppressed by obesity. 
We developed a technique to integrate single cell data with bulk RNA-seq data to assess β-cell-
specific differential expression. While the list of genes identified as β-cell-specific is only 316 
genes, sub-setting the bulk RNA-seq data by β-cell-specific genes provided a small but highly-
focused search space to identify genes that influence β-cell function in hyperglycemic-obesity, 
normoglycemic-obesity, and healthy mice. We identified Pdyn as a novel candidate gene 
associated with improved glycemic control in males. While Pdyn’s role in β-cell function is 
unknown, many opioids modulate insulin section391. Pdyn is over expressed in Beta 2 cells, 
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which are increased in normoglycemic-obese mice, and may link improved β-cell function with 
hypoxia response, as Pdyn provides protection from hypoxia in lung and neuronal tissue378,379. 
Weighted gene co-expression network analysis (WGCNA) identified β-cell-specific 
modules that correlate with phenotypes. The blue module is highly expressed in 20wk high-fat 
males, strongly correlating with blood glucose concentration, and enriched with fatty acid 
metabolism genes, which are heavily implicated in obesity and diabetes. Since fatty acid 
metabolism can stimulate insulin release, it is possible that prolonged activation of this network 
promotes elevated basal insulin secretion but inhibits GSIS. Expression of this network may be 
related to the abundance of Beta 1 cells in 20k high-fat males, which are geared toward basal 
insulin release. The brown module is highly expressed in lean mice and negatively correlates 
with serum insulin levels and enriched for genes associated with β-cell physiology. This network 
is suppressed in 20wk high-fat males, who have dysfunctional β-cells. We homed in on 
Fam151a, a gene highly connected within the network, that independently correlates with serum 
insulin levels. Fam151a is both differentially expressed and differentially connected within the 
brown module between 20wk high-fat and 20wk low-fat mice, suggesting an important role 
within the network and a potential link between serum insulin levels and β-cell function.  
We explored if subpopulation composition contributes to differential expression of Pdyn 
and Fam151a. Total Pdyn expression increased across all β-cells between 20 and 30wk high-fat 
fed males, in agreement with the bulk RNA-seq data. Pdyn is overexpressed in Beta 2 cells, 
which increase in proportion between 20 and 30 weeks in high-fat mice, suggesting differential 
expression of Pdyn is driven by a change in subpopulation proportions. Likewise, total Fam151a 
increased across all β-cells between 20wk high and low-fat males, in agreement with the bulk 
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RNA-seq data. However, Fam151a is strongly overexpressed in Beta 1 cells, which are most 
abundant in 20wk high-fat males. To explore this discrepancy, we performed differential 
expression analysis in Beta 1 cells between 20wk high and 20wk low-fat males and found 
Fam151a expression is significantly higher in 20wk low-fat male Beta 1 cells. Thus, while the 
proportion of Beta 1 cells is lower in 20wk low-fat mice, the expression of Fam151a is 
significantly increased in their Beta 1 cells. 
In conclusion, obese SM/J mice experience improved beta cell function, characterized by 
enhanced GSIS, decreased basal insulin secretion, and increased islet insulin content. Underlying 
this improvement is a decrease in β-cells associated with basal insulin secretion, and an increase 
β-cells associated with hypoxia response. Concurrently, obese SM/J mice decrease expression of 
a gene network associated with fatty acid metabolism. Expression of key genes, including Pdyn 
and Fam151a, provide strong candidates for exploring differential gene expression between and 
within β-cell subpopulations, and how changes in subpopulation structure influence glycemic 
control in obesity. 
4.2 Future Directions 
My thesis work characterized how obese SM/J β-cells change at the morphological, 
functional, and transcriptional level. I established that improved β-cell function underlies the 
restoration of glycemic control and identified genetic pathways associated with the 
hyperglycemic-obese state. While other strains, including LG/J and C57Bl/J6, do not improve 
glycemic control with age on a high fat diet, this phenomenon has not been rigorously assessed 
in most inbred mouse strains. Performing this experiment on other inbred strains, particularly 
those that are susceptible to diet-induced obesity, would reveal if reestablishing glycemic control 
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is truly unique to SM/J mice. A genomic analysis between strains would reveal the genetic 
variants that are unique to the SM/J strain, providing candidates that contribute to reestablishing 
glycemic control in obesity. This would pave the way for identifying the genetic mechanisms 
underlying the resolution of hyperglycemia in SM/J mice, providing candidate genes and 
pathways. 
The obese SM/J mouse model could be explored in greater depth to characterize the 
physiological changes underlying the reestablished glycemic control. Insulin production and 
insulin sensitivity are tightly intertwined. While insulin tolerance tests provide a snapshot of 
insulin sensitivity, they do not provide a dynamic perspective on the glucose-insulin axis. A 
hyperglycemic clamp would assess insulin secretion in vivo by measuring insulin levels when 
hyperglycemia is induced by continuous glucose infusion. This would confirm if the 
improvement in β-cell function is maintained outside of cultured conditions. Likewise,  a 
hyperinsulinemic-euglycemic clamp would assess insulin sensitivity in real time. By infusing a 
constant level of insulin while infusing variable levels of glucose to maintain equilibrium, true 
insulin sensitivity could be assessed. This would reveal the degree to which obese SM/J mice 
improve insulin sensitivity over time. Similarly, a time course experiment could reveal the 
precise order of events, addressing if improved insulin sensitivity precedes the increase in insulin 
production, or vise versa. Examining insulin sensitivity and insulin levels every two weeks over 
the 20–30 week range would establish if the improved beta cell function can be attributed to 
improvement in insulin sensitivity of metabolic tissues (extrinsic factors) or improved insulin 
secretion (intrinsic factors). 
Performing islet transplants on obese SM/J mice would also provide insight into the 
nature of the improved β-cell function. After treatment, ablation of existing β-cells using STZ or 
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a genetic knockout can address if an islet removed from 30wk high fat mice is sufficient to 
reestablish glycemic control in 20wk high fat mice. Conversely, transplant experiments can 
address if islets from 20wk high fat mice spontaneously improve when transplanted into 30wk 
mice, or will if render the mice diabetic. Further, we can ask if islets from 20wk high fat mice 
render lean, normoglycemic mice diabetic. If islets from 30wk obese mice improve glycemic 
control in younger obese mice, then we can conclude that the improved β-cell function is 
intrinsic, and not primarily driven by the islet microenvironment. Likewise, if islets transplanted 
from hyperglycemic obese mice improve in 30wk obese mice, we can conclude that the 
improvement in β-cell function can be attributed to decreased glycemic stress, suggesting the 
improvement is driven by extrinsic factors. If the improvement is driven by extrinsic factors, 
focus should shift to other metabolic tissues in the obese SM/J mouse. 
Using immunohistochemistry to stain pancreatic sections for subpopulation 
overexpressed genes may verify the existence of the subpopulations at the protein level. Other 
gene quantification techniques, such as seqFISH, can confirm differential expression between 
subpopulations. If the β-cell subpopulations can be confirmed using imaging techniques, the 
effects of genetic knockouts and islet transplantation on subtype composition could be assessed, 
helping confirm or reject a role for subpopulation structure in the resolution of hyperglycemia. 
Topographical analysis would assess if β-cell subpopulations localize to the islet core or 
periphery, or are in proximity to neurons, blood vessels, or other islet cell types, providing 
insight into how microenvironment may contribute to the improved β-cell function. If there are 
meaningful differences in protein level among subpopulations, cell sorting would allow for 
subpopulations to be isolated and reaggregated for analysis, including functional assessment and 
gene expression profiling.  
100 
 
Generating β-cell-specific knockouts of Pdyn and Fam151a in the SM/J genetic 
background would allow for examination of each gene in the context of improved glycemic 
control in obesity. I hypothesize that ablation of Pdyn will decrease glucose-stimulated insulin 
secretion in vivo due to decreased vasodilation but will not affect insulin secretion ex vivo. 
Further, I hypothesize treatment with a fatty acid oxidation inhibitor may improve insulin 
secretion in 20wk obese islets, including improving GSIS and decreasing basal insulin secretion. 
The effects of fatty acid oxidation inhibitor treatment in vivo will be difficult to untangle among 
the changes associated with inhibited fatty acid metabolism in other tissues, but it would be 
interesting to see if this could alter the proportion of basal insulin secreting β-cells. These 
experiments would confirm the importance of the gene expression changes seen in obese SM/J β-
cells and would warrant exploration in human β-cell models. 
The data integration strategy developed here can be applied to other cell types, including 
α-cells. Dysfunction of α-cells has been associated with diabetes and obesity and may also 
provide potential avenues for treatment. Identification of α-cell-specific genes would allow for 
similar assessment of differential expression and genetic networks associated with the hyper- and 
normoglycemic obese states. Although analyzing α-cells was outside the scope of this thesis, I 
hypothesize α-cell function and gene expression changes during the resolution of hyperglycemia, 
and further analysis is likely to uncover candidate genes associated with improved glycemic 
control. This data integration strategy could also be applied to healthy and diabetic human islet 
datasets, as bulk islet RNA-seq data is in much greater abundance than β-cell scRNA-seq data. 
Knockdowns of candidate genes could be performed in human iPSC’s to assess how the gene 
contributes to differentiation into a β-cell-like cells, which could improve the efficiency or 
function of generating β-cells in vitro. 
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